Clinical trial NCT02669615
Conditions: Multiple Myeloma
Keywords: multiple myeloma Melphalan HCl Autologous Transplantation
Sponsor: Medical College of Wisconsin
Start date: 2016-11-01; Completion date: 2017-07-19
Enrollment: 24 participants; Allocation: NA; Intervention model: SINGLE_GROUP

Brief summary:
This study is a single-center, open-label study of high-dose Melphalan HCl (hydrochloric acid) for injection (propylene glycol-free Melphalan) conducted in 24 patients, who have symptomatic multiple myeloma and qualify for autologous stem-cell transplantation (ASCT).

There will be three distinct evaluation periods in this trial: a pretreatment period, a study period and a follow-up period.

Detailed description:
OVERVIEW: This study is a single-center, open-label study of high-dose Melphalan HCl for injection (propylene glycol free Melphalan) conducted in 24 patients, who have symptomatic multiple myeloma and qualify for ASCT.

There will be three distinct evaluation periods in this trial: a pretreatment period, a study period and a follow-up period.

PRETREATMENT:

Pretreatment Period Evaluations (Days -30 to -3). Baseline assessments will be collected within 30 days of dosing with Melphalan HCl for injection (propylene glycol free), after the patient has signed the informed consent. These include clinical and laboratory assessments (e.g., medical history and physical examination, hematology, urine analysis, creatinine clearance), chest X-ray and vital signs.

STUDY TREATMENT:

1. During the study period, patients will receive 200 mg/m\^2 of Melphalan HCl for injection (propylene glycol free) as a one-time infusion on day
2. Following one day of rest after the myeloablative Melphalan conditioning (day -1), patients will receive an autologous graft with a minimum cell dose of 2 × 106 CD34+ cells/kg of patient body weight (day 0).
3. Pharmacokinetic, efficacy and safety evaluations will be performed during the study period.

FOLLOW-UP:

ASCT Day +1 until Day+100. During the follow-up period, patients will return for daily laboratory tests (hematology and basic serum chemistry) and will be evaluated weekly by their physicians until the engraftment date, with the final end-of-study evaluation occurring up to seven days after engraftment date. During the follow-up period, the tests (e.g., physical examination, CBC, vital signs, full serum chemistry panel, bone marrow biopsy) will be performed weekly until engraftment (unless otherwise specified).

Arms: arm 1: Patients will receive 200 mg/m\^2 of Melphalan HCl for injection (propylene glycol free) as a one-time infusion on day 2. Blood samples for the pharmacokinetic (PK) evaluation of melphalan will be collected after melphalan dosing (day -2). Following one day of rest after the myeloablative Melphalan conditioning (day -1), patients will receive an autologous graft with a minimum cell dose of 2 × 106 CD34+ cells/kg of patient body weight (day 0).
Interventions: intervention 1: Melphalan HCl for injection (propylene glycol free)
Intervention descriptions: intervention 1: During the study period, patients will receive 200 mg/m\^2 of Melphalan HCl for injection (propylene glycol free) as a one-time infusion on day 2.

Protocol documents:
Prot_000.pdf: 
 
1 
 
 A Phase II, Open-Label, Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl 
for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous 
Transplantation (IIS-MEL-MCW-001) 
Investigational Product: 
Melphalan Hydrochloride (HCl) for Injection (Propylene Glycol 
Free)  
Indication Studied: 
Myeloablative Conditioning in Multiple Myeloma Patients 
Undergoing Autologous Transplantation 
Funding agency: 
Spectrum 
Phase:                                  Phase II 
Protocol history:  
Original : 9/17/2015 (version 1.1) 
Version 2:  01/20/2016  
Version 3:  01/22/2016 
Version 4:  01/23/2016 
Version 5:  01/24/2016 
Version 6:  01/28/2016 
Version 7:  01/29/2016 
Version 8:  02/11/2016 
Version 9:  02/11/2016 (4:03 p.m.) 
Version 10:  02/16/2016 
Version 11:  02/20/2016 
 
Investigator and Study Center: 
 
Parameswaran Hari, MD 
Medical College of Wisconsin  
Division of Hematology and Oncology 
9200 W. Wisconsin Avenue 
Milwaukee, WI 53226 
414.805.4600 
Email address: phari@mcw.edu 
 
 
 
 
Co-I :  Binod Dhakal, MD 
Hematology – Oncology Fellow 
Medical College of Wisconsin  
Division of Hematology and Oncology 
9200 W. Wisconsin Ave. 
Milwaukee, WI 53226 
414.805.4600 
Sub-I: Timothy Fenske, MD 
Associate Professor of Medicine  
Medical College of Wisconsin 
Division of Hematology and Oncology 
9200 W. Wisconsin Ave. 
Milwaukee, WI 53226 
Sub-I: Marcelo Pasquini, MD  
Associate Professor of Medicine 
 Medical College of Wisconsin 
Division of Hematology and Oncology 
9200 W. Wisconsin Ave. 
Milwaukee, WI 53226 


 
2 
 
414.805.4600 
 
414.805.4600 
Sub-I: Mehdi Hamadani, MD  
Associate Professor of Medicine 
Medical College of Wisconsin 
Division of Hematology and Oncology 
9200 W. Wisconsin Ave. 
Milwaukee, WI 53226 
414.805.4600 
Sub-I: Anita D’Souza, MD 
Assistant Professor of Medicine 
 Medical College of Wisconsin 
Division of Hematology and Oncology 
9200 W. Wisconsin Ave. 
Milwaukee, WI 53226 
414.805.4600 
 
 
Sub-I: Mary Horowitz, MD 
Professor of Medicine 
Medical College of Wisconsin 
Division of Hematology and Oncology 
9200 W. Wisconsin Ave. 
Milwaukee, WI 53226 
414.805.4600 
 
 
Sub-I: William Drobyski, MD 
Professor of Medicine 
Medical College of Wisconsin 
Division of Hematology and Oncology 
9200 W. Wisconsin Ave. 
Milwaukee, WI 53226 
414.805.4600 
Sub-I: Douglas Rizzo, MD 
Professor of Medicine 
Medical College of Wisconsin 
Division of Hematology and Oncology 
9200 W. Wisconsin Ave. 
Milwaukee, WI 53226 
414.805.4600 
 
Biostatistics: 
James Anderson, PhD 
Professor of Biostatistics 
Medical College of Wisconsin 
9200 W. Wisconsin Ave. 
Milwaukee, WI  53226 
Research Coordinator: 
Debra Pastorek 
Medical College of Wisconsin  
9200 W. Wisconsin Avenue 
Milwaukee, WI  53226 
414.805.6837 
 
 
 
This is an investigator-initiated study.  Parameswaran Hari, the principal investigator who may 
also be referred to as the sponsor-investigator, is conducting the study and acting as the sponsor.  
Therefore, the legal/ethical obligations of the principal investigator include both those of a 
sponsor and those of an investigator.


 
 
Propylene Glycol-Free Melphalan 200 
 
3 
 
Protocol Approval Signature Page 
 
Protocol:  
IIS-MEL-MCW-001 
Protocol Title: 
A Phase II, Open-Label, Pharmacokinetic Study of Propylene Glycol-Free 
Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma 
Patients Undergoing Autologous Transplantation 
 
 
 
 
 
 
 
 
 
 
 
 
 
Date 
 


 
 
Propylene Glycol-Free Melphalan 200 
 
4 
 
Clinical Study Protocol Agreement  
Protocol 
IIS-MEL-MCW-001 
Protocol Title: 
A Phase II, Open-Label, Pharmacokinetic Study of Propylene Glycol-Free 
Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma 
Patients Undergoing Autologous Transplantation 
 
 
 
 
 
I have carefully read this protocol and agree that it contains all of the necessary information 
required to conduct this study.  I agree to conduct this study as described and according to the 
Declaration of Helsinki, International Conference on Harmonization Guidelines for Good 
Clinical Practices, and all applicable regulatory requirements. 
 
 
 
 
 
 
Investigator’s Signature 
 
Date 
 
 
 
 
 
Name (Print) 
 
 


 
 
Propylene Glycol-Free Melphalan 200 
 
5 
 
Table of Contents 
Description 
Page 
1 SYNOPSIS .............................................................................................................................. 9 
2 LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS .................................. 17 
3 INTRODUCTION................................................................................................................ 19 
3.1 
Background ..................................................................................................................... 19 
3.2 
Nonclinical Experience ................................................................................................... 20 
3.3 
Previous Clinical Experience .......................................................................................... 21 
3.4 
Rationale for Study and Dose Selection ......................................................................... 24 
4 STUDY OBJECTIVES ........................................................................................................ 25 
4.1 
Objectives ....................................................................................................................... 26 
4.1.1 
Primary Objective ................................................................................................... 26 
4.1.2 
Secondary Objective(s) ........................................................................................... 26 
4.2 
Study End Points ............................................................................................................. 26 
4.2.1 
Primary End Point ................................................................................................... 26 
4.2.2 
Secondary End Points ............................................................................................. 26 
4.2.2.1 
CR Rates, TRM, Myeloablation and Engraftment ...................................... 26 
4.2.2.2 
Safety Assessments ..................................................................................... 27 
5 STUDY DESIGN .................................................................................................................. 28 
5.1 
Overall Study Design and Plan ....................................................................................... 28 
5.1.1 
Pretreatment Period (Day -30 to Day -3) ................................................................ 28 
5.1.2 
Study Period (Day -2 to Day 0) .............................................................................. 28 
5.1.3 
Follow-up Period (Day +1 to Date of Engraftment) ............................................... 28 
5.2 
Study Schema ................................................................................................................. 29 
5.3 
Stopping Rules ................................................................................................................ 31 
6 SELECTION AND WITHDRAWAL OF SUBJECTS ........ Error! Bookmark not defined. 
6.1 
Inclusion Criteria ............................................................................................................ 31 
6.2 
Exclusion Criteria ........................................................................................................... 31 
6.3 
Withdrawal Criteria ........................................................................................................ 32 
7 TREATMENTS, CONCOMITANT THERAPY, AND DOSE 
MODIFICATIONS .............................................................................................................. 34 
7.1 
Treatments Administered ................................................................................................ 34 


 
 
Propylene Glycol-Free Melphalan 200 
 
6 
 
7.2 
Identity of Study Product(s) ............................................................................................ 34 
7.2 
Investigational Product ........................................................................................... 34 
7.3 
Assigning Subjects to Treatment Group ......................................................................... 35 
7.4 
Study Medication Accountability ................................................................................... 35 
7.5 
Blinding/Masking of Treatments .................................................................................... 35 
7.6 
Treatment Compliance .................................................................................................... 35 
7.7 
Prior and Concomitant Therapies ................................................................................... 36 
7.7.1 
Anticancer or Experimental Therapy ...................................................................... 36 
7.7.2 
Hematopoietic Growth Factors ............................................................................... 36 
7.7.3 
Prophylactic Treatment for Opportunistic Infections ............................................. 36 
7.7.4 
Antiemetics ............................................................................................................. 36 
7.7.5 
Antidiarrheals .......................................................................................................... 36 
7.7.6 
Blood Products ........................................................................................................ 36 
7.7.7 
Other Concomitant Medications ............................................................................. 36 
7.8 
Dose Modifications for Drug-Related SAEs and/or Toxicities ...................................... 37 
8 STUDY CONDUCT ............................................................................................................. 37 
8.1 
Overview of Data Collection .......................................................................................... 37 
8.2 
Description of Study Days .............................................................................................. 39 
8.2.1 
Pre-Treatment Period (Day -30 to Day -3) ............................................................. 39 
8.2.2 
Study Period (Day -3 to Day 0) .............................................................................. 39 
8.2.2.1 
Day -2 .......................................................................................................... 40 
8.2.2.2 
Day -1 .......................................................................................................... 40 
8.2.2.3 
Day 0 ........................................................................................................... 41 
8.2.3 
Follow-up Period (ASCT Day +1 to Date of Engraftment) .................................... 41 
8.2.3.1 
Week 1 (Day +7 ± 2 Days) ......................................................................... 41 
8.2.3.2 
Week 2 (Day +14 ± 2 Days ), Week 3 (Day +21 ± 2 Days) 
and Week 4 (Day +28 ± 2 Days) (Optional Visits Dependent 
on Date of Engraftment) .............................................................................. 42 
8.2.3.3 
End of Study Evaluation (Day 100) or Study 
Discontinuation/Early Termination ............................................................. 42 
8.3 
Methods of Data Collection ............................................................................................ 43 
8.3.1 
Pharmacokinetic Evaluations .................................................................................. 43 
8.3.1.1. Pharmacokinetic Blood Sampling ............................................................... 43 


 
 
Propylene Glycol-Free Melphalan 200 
 
7 
 
8.3.2 
Efficacy Evaluations ............................................................................................... 44 
8.3.2.1 
Hematology Parameters for Myeloablation and Engraftment ..................... 44 
8.3.3 
Safety Evaluations .................................................................................................. 44 
8.3.3.1 
Adverse Event Assessment ......................................................................... 44 
8.3.3.2 
Clinical Laboratory Investigations .............................................................. 45 
8.3.3.3 
ECOG Performance Status .......................................................................... 46 
8.3.3.4 
Body Weight, Height, and Body Surface Area ........................................... 46 
8.3.3.5 
Physical Examinations ................................................................................ 46 
8.3.3.6 
Vital Signs ................................................................................................... 46 
9 ADVERSE EVENT MANAGEMENT .............................................................................. 47 
9.1 
Definition of an Adverse Event ...................................................................................... 47 
9.2 
Definition of a Serious Adverse Event ........................................................................... 47 
9.3 
Recording of Adverse Events and Serious Adverse Events ........................................... 48 
9.4 
Intensity of Adverse Events ............................................................................................ 48 
9.5 
Relationship of Adverse Events to Study Drug .............................................................. 48 
9.6 
Follow-Up of Adverse Events and Serious Adverse Events .......................................... 49 
9.7 
Post-Study Adverse Events and Serious Adverse Events ............................................... 49 
9.8 
 Regulatory Aspects of Adverse Event Reporting .......................................................... 49 
10 STATISTICAL METHODS ............................................................................................... 49 
10.1 Data Collection Methods ................................................................................................ 50 
10.2 Statistical Analysis Plan .................................................................................................. 50 
10.3 Sample Size Estimates .................................................................................................... 50 
10.4 Analysis Populations ....................................................................................................... 50 
10.5 Interim and End of Study Analyses ................................................................................ 50 
10.6 Pharmacokinetic Analyses .............................................................................................. 51 
10.7 Efficacy Analyses ........................................................................................................... 51 
10.7.1 Efficacy Endpoints .................................................................................................. 51 
10.7.2 Analysis of Efficacy Endpoints .............................................................................. 52 
10.8 Safety Analyses ............................................................................................................... 52 
10.9 General Issues for Statistical Analysis ............................................................................ 52 
10.9.1 Multiple Comparisons and Multiplicity .................................................................. 52 
10.9.2 Sub-Groups ............................................................................................................. 53 
10.9.3 Missing Data ........................................................................................................... 53 


 
 
Propylene Glycol-Free Melphalan 200 
 
8 
 
11 STUDY ADMINISTRATION............................................................................................. 53 
11.1 Regulatory and Ethical Considerations ........................................................................... 53 
11.1.1 Regulatory Authority Approvals............................................................................. 53 
11.1.2 Institutional Review Board Approvals.................................................................... 53 
11.1.3 Subject Informed Consent....................................................................................... 53 
11.2 Study Monitoring ............................................................................................................ 54 
11.3 Quality Assurance ........................................................................................................... 54 
11.4 Study Termination and Site Closure ............................................................................... 54 
11.5 Records Retention ........................................................................................................... 54 
11.6 Study Organization ......................................................................................................... 55 
11.6.1 Data Safety Monitoring Board ................................................................................ 55 
11.7 Confidentiality of Information ........................................................................................ 55 
11.8 Study Publication ............................................................................................................ 56 
12 REFERENCES ..................................................................................................................... 56 
13 APPENDIX I ........................................................................................................................ 59 
 
 


 
 
Propylene Glycol-Free Melphalan 200 
 
9 
 
1 SYNOPSIS 
Protocol Number IIS-MEL-MCW-001 
Title 
A Phase II, Open-Label, Pharmacokinetic Study of Propylene Glycol-Free Melphalan 
HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing 
Autologous Transplantation 
Investigators/ 
Study Sites 
This is a single-center study that will be conducted at the Medical College of 
Wisconsin. 
Study Duration 
and Dates 
This study is expected to start October 2015 and will take approximately six months to 
enroll 24 patients. 
Phase 
Phase II 
Objectives 
Primary 
To assess the pharmacokinetics (PK) of Melphalan HCl for injection (propylene glycol 
free) at a single-day dose of 200 mg/m2 in multiple myeloma (MM) patients undergoing 
autologous stem cell transplant (ASCT). 
Secondary 
1. To determine complete response (CR) rates at day 100 of MM patients 
receiving Melphalan HCl for injection (propylene glycol free) at a single dose 
of 200 mg/m2. 
2. To determine the TRM, myeloablation and subsequent neutrophil engraftment 
in MM patients receiving high-dose Melphalan HCl for injection (propylene 
glycol free) followed by ASCT. 
3. To describe the overall safety of Melphalan HCl for injection (propylene glycol 
free) at a single dose of 200 mg/ m2. 
Number of 
Patients 
Twenty-four patients, who have symptomatic MM (per International Working Group 
Criteria), and qualify for ASCT. 
Planned Number 
of Sites 
One (1) (Medical College of Wisconsin) 
Study Design 
This study will be a single center, open-label study of high-dose Melphalan HCl for 
injection (propylene glycol free Melphalan) conducted in 24 patients, who have 
symptomatic MM and qualify for ASCT. 
There will be three distinct evaluation periods in this trial:  a pretreatment period, a 
study period, and a follow-up period.  The specific tests performed during each period 
are described below. 


 
 
Propylene Glycol-Free Melphalan 200 
 
10 
 
Study Design 
(continued) 
Pretreatment Period Evaluations (Days -30 to -3) 
The following baseline assessments should be collected within 30 days of dosing with 
Melphalan HCl for injection (propylene glycol free), after the patient has signed the 
informed consent: 
• 
Medical history and physical examination, including prior MM treatments and the 
response. 
• 
Prior and concomitant medications. 
• 
Eastern Cooperative Oncology Group (ECOG) performance status. 
 
• 
Infectious disease testing:  Serum titers for cytomegalovirus (CMV), herpes 
simplex virus (HSV), Epstein-Barr virus (EBV), hepatitis panel, West Nile Virus 
(WNV), rapid plasma regain (RPR) for syphilis, human immunodeficiency virus 
(HIV) and human T-lymphotropic virus (HTLV1) antibodies. 
• 
Hematology (CBC with manual differential and reticulocyte count). 
• 
Urine analysis 
• 
Serum chemistry (sodium, potassium, chloride, magnesium, bicarbonate, glucose, 
total protein, albumin, calcium, phosphate, uric acid, BUN, creatinine, total 
bilirubin, alkaline phosphatase, LDH, SGOT, SGPT and creatinine clearance 
[measured or calculated/estimated]). 
• 
Creatinine clearance (calculated/estimated or collected). 
• 
Chest X-ray. 
• 
Vital signs (systolic and diastolic blood pressures, heart rate, respiration rate and 
body temperature), including height, weight and body surface area (BSA). 
• 
Serum pregnancy test for women of childbearing potential.  Women are considered 
to be of childbearing potential unless they have had no menses for at least 
12 months. 
 
Study Period  (Day -2 to Day 0) 
During the study period, patients will receive 200 mg/m2 of Melphalan HCl for 
injection (propylene glycol free) as a one-time infusion on day -2.  Blood samples for 
the pharmacokinetic (PK) evaluation of melphalan will be collected after melphalan 
dosing (day -2).   
 
Following one day of rest after the myeloablative Melphalan conditioning (day -1), 
patients will receive an autologous graft with a minimum cell dose of 2 × 106 CD34+ 
cells/kg of patient body weight (day 0).  Cryopreservation and thawing of product will 
be consistent with Foundation for the Accreditation of Cellular Therapy (FACT) 
standards and local institutional practice.  The graft will be infused per institutional 
protocol. Per institutional autologous transplant protocol guideline,  Filgrastim will be 
administered daily starting day +5 after transplant for patients receiving transplant as 
in-patient. For outpatient transplantation, per institutional protocol PEG-filgrastrim will 
be administered on day +1 as a single dose. All patients will receive antiemetics, 
hydration and infection prophylaxis according to institutional guidelines.     


 
 
Propylene Glycol-Free Melphalan 200 
 
11 
 
Study Design 
(continued) 
The following PK, efficacy and safety evaluations will be performed at the following 
time points during the study period:  
• 
Ten (10) blood samples at specific time points (see PK assessments) for the PK 
evaluation will be collected immediately prior to and after receiving Melphalan 
HCl for injection (propylene glycol free) on day -2. 
• 
Vital signs (systolic and diastolic blood pressures, heart rate and respiration rate) 
will be recorded prior to dosing and hourly during the first four hours after 
receiving Melphalan.  
• 
Physical examination will be performed prior to dosing of Melphalan HCl for 
injection (propylene glycol free) on day -2. 
• 
CBC with differential will be performed prior to dosing of Melphalan on day -2. 
• 
Full serum chemistry panel (sodium, potassium, chloride, magnesium, bicarbonate, 
glucose, total protein, albumin, calcium, phosphate, uric acid, BUN, creatinine, 
total bilirubin, alkaline phosphatase, LDH, SGOT, SGPT and creatinine clearance 
[measured or calculated/estimated]) will be performed prior to Melphalan dosing.  
• 
Toxicity grading and evaluation for AEs/SAEs according to National Cancer 
Institute Common Toxicity Criteria for AEs Version 4.0 (CTCAE v4.0) grade will 
occur during the entire study period. 
• 
Concomitant medications will be recorded during the entire study period. 
Follow-Up Period (ASCT Day +1 until Day+100) 
During the follow-up period, patients will return for daily laboratory tests (hematology 
and basic serum chemistry) and will be evaluated weekly by their physicians until the 
engraftment date, with the final end-of-study evaluation occurring up to seven days 
after engraftment date.  During the follow-up period, the following tests will be 
performed weekly until engraftment (unless otherwise specified) and the data captured 
in the CRF: 
• 
Basic serum chemistry panel daily until neutrophil engraftment. 
• 
CBC with manual differential daily until neutrophil engraftment. 
• 
Physical examination.  
• 
Vital signs (systolic and diastolic blood pressures, heart rate, respiration rate and 
body temperature) and body weight. 
• 
Full serum chemistry panel (sodium, potassium, chloride, magnesium, bicarbonate, 
glucose, total protein, albumin, calcium, phosphate, uric acid, BUN, creatinine, 
total bilirubin, alkaline phosphatase, LDH, SGOT, SGPT and creatinine clearance 
[measured or calculated/estimated]) at least twice weekly until day 21 or 
engraftment, whichever is later. 
• 
Multiple myeloma panel 
• 
Bone marrow biopsy 
• 
Toxicity grading and evaluation for AEs/SAEs according to NCI-CTC AE 
Version 4.0 will occur until study discharge or AE follow-up is complete. 
• 
Concomitant medications. 


 
 
Propylene Glycol-Free Melphalan 200 
 
12 
 
Study Population 
Study Population and Main Criteria for Inclusion/Exclusion 
Inclusion 
• 
Patients with symptomatic MM requiring treatment at diagnosis or anytime 
thereafter. 
• 
Patients with MM, who qualify for ASCT therapy and have received pretransplant 
therapy for transplantation. 
• 
Adult patients (≥18 years of age) meeting institutional criteria to receive a total 
melphalan dose of 200 mg/m2 as a conditioning regimen, as approved by 
institutional PI.  
• 
Patients with an adequate autologous graft, which is defined as an unmanipulated, 
cryopreserved, peripheral blood stem cell graft containing at least 2 × 106 CD34+ 
cells/kg, based on patient’s actual weight. 
• 
Patients with adequate organ function as measured by: 
 
Cardiac:  Left ventricular ejection fraction at rest >40% (documented within 30 
days prior to day -3). 
 
Hepatic:  Bilirubin <2 × the upper limit of normal (ULN) and ALT/AST 
<3 × ULN. 
 
Renal:  Creatinine clearance >40 mL/min (measured or calculated/estimated). 
 
Pulmonary:  Adjusted DLCO, FEV1, FVC >50% of predicted value (corrected 
for Hgb) (documented within 30 days prior to day -3) 
Exclusion 
• 
Patients with systemic AL amyloidosis. 
• 
ECOG performance status ≥2. 
• 
Patients with uncontrolled hypertension. 
• 
Patients with an active bacterial, viral or fungal infection. 
• 
Patients with prior malignancies, except resected basal cell carcinoma or treated 
cervical carcinoma in situ.  Cancer treated with curative intent >5 years previously 
will be allowed.   
• 
Female patients who are pregnant (positive ß-HCG) or breastfeeding. 


 
 
Propylene Glycol-Free Melphalan 200 
 
13 
 
Study Population 
• 
Female patients of childbearing potential, who are unwilling to use adequate 
contraceptive techniques during and for one month following study treatment with 
Melphalan HCl for injection (propylene glycol free). 
• 
Patients seropositive for HIV. 
• 
Concurrent clinical trials for post-transplant therapy of myeloma are permitted 
provided such studies do not involve conditioning therapy. 
• 
Patients who are unwilling to provide informed consent. 
• 
Patients who are hypersensitive or intolerant to any component of the study drug 
formulation. 
Study 
Treatments 
During the study period, patients will receive 200 mg/m2 of Melphalan HCl for 
injection (propylene glycol free) on day -2 prior to ASCT.   
Melphalan HCl for injection (propylene glycol free) will be diluted with normal saline 
to a concentration of no greater than 2  mg/mL and infused over 30 minutes via a 
central venous catheter.   
For the BSA calculation, actual body weight should be used for patients who weigh less 
than or between 100 and 130% of their ideal body weight (IBW).  For patients who 
weigh more than 130% of their IBW, BSA should be calculated based on adjusted body 
weight. 
Pharmacokinetic 
Assessments 
Seven mL venous blood samples for the PK analysis of melphalan will be withdrawn 
through an indwelling peripheral intravenous cannula at 0 (predose), 10, 20, 30, 60, 90, 
120, 180, 240 and 360 minutes (±5 minutes) after the completion of infusion. The 
predose blood sample will be collected within 60 minutes prior to the dose of 
Melphalan HCl for injection (propylene glycol free).  These blood samples will be used 
to measure concentrations of total melphalan.  PK evaluation will be based on the 
determination of the following parameters for total melphalan, including (but not 
limited to):  AUC0–t, AUC0–∞, Cmax, Tmax, t1/2, and kel. (Blood samples for PK analysis 
should not be drawn from the same IV line used  to administer the melphalan.) 


 
 
Propylene Glycol-Free Melphalan 200 
 
14 
 
Efficacy 
Assessments 
The efficacy end points collected are rates of myeloablation, engraftment and myeloma 
response. Collection of hematology parameters (RBC, hemoglobin, hematocrit, platelet 
count, WBC with manual differential and reticulocyte count) daily until engraftment 
will be used to determine these using the following definitions:   
Myeloablation is defined as any one of the following: 
• 
ANC < 0.5 × 109/L. 
• 
Platelet count < 20,000/mm3. 
The first of two consecutive days for which cell counts drop below these cut-off levels 
will be recorded as the myeloablation date. 
 
 
Engraftment: ANC recovery is defined as an absolute neutrophil count (ANC) of ≥ 0.5 
x 10^9 /L (500/mm3 ) for three consecutive laboratory values obtained on different 
days. Date of ANC recovery is the date of the first of three consecutive laboratory 
values where the ANC is ≥ 0.5 x 10^9 /L. Platelet recovery is reported when the 
recipient’s platelet count is ≥ 20 x 10^9 /L seven days after platelet transfusion and is 
maintained for three consecutive lab values obtained on different days. 
 
International Myeloma Working Group-defined uniform response criteria will be used 
to assess myeloma response at day 100. 
Safety 
Assessments 
Safety measures collected during the Pretreatment Period (Day -30 to Day -3) will 
include:  physical examination, ECOG performance status, infectious disease testing 
(serum titers for CMV, HSV, EBV, WNV, RPR for syphilis, hepatitis panel, and HIV 
and HTLV1 antibodies), clinical laboratory tests (hematology, serum chemistry), chest 
X-ray, vital signs (including height, weight and BSA).   
Safety measures collected during the Study Period (Day -3 to Day 0) will include:  
SAEs, AEs, vital signs, clinical laboratory assessments (hematology, serum chemistry), 
physical examination findings, ECOG performance status.  These tests will be 
performed prior to administration of Melphalan HCl for injection (propylene glycol 
free) on day -2.   
 
Safety measures collected during the Follow-Up Period (Day + 1 to Day +100) will 
include:  physical examination findings, ECOG performance status, AEs/SAEs, vital 
signs (including body weight, hematology, serum chemistry and  urinalysis. 


 
 
Propylene Glycol-Free Melphalan 200 
 
15 
 
Statistical 
Procedures 
Analysis Populations 
The PK evaluable population is defined as all patients who completed dosing and 
adequate subsequent PK blood draws for the calculation of AUC and Cmax. PK analyses 
will be performed on the evaluable population. 
The population is defined as all patients who are enrolled and received study drug.  All 
safety and efficacy analyses will be performed on patients who received study drug. 
 
Sample Size Justification 
A sample size of 24 patients is planned for this study.  The mean ± SD results of 
AUC0-t and Cmax of 100 mg/m2 Melphalan dose from a previously conducted study 
were 376,577±93,401 min·ng/mL and 4374 ± 1050 ng/mL respectively. Twenty-four 
patients will provide ±10% width for the 90% CI around the point estimates of AUC0-t 
and Cmax in this study.  A study size of 24 patients would also provide for a 95% 
confidence interval having a width of ±20% to estimate an AE incidence rate for 
common AEs occurring at a frequency of 25 -30%.   
 
Pharmacokinetic Analyses 
PK parameters will be determined by nonparametric PK data analysis techniques.  PK 
parameters computed from plasma drug concentration-time data will include, but not 
necessarily be limited to, the following: 
• 
Cmax derived from the individual raw data. 
• 
tmax derived from the individual raw data. 
• 
Apparent terminal first-order elimination rate constant (kel). 
• 
Apparent elimination t1/2. 
• 
Area under the plasma concentration time curve to the last measurable time point 
(AUC0–t) calculated by the trapezoidal rule. 
• 
Area under the plasma concentration time curve to infinity (AUC0–∞):   
AUC0–t + area under the plasma concentration time curve from the last measurable 
time point extrapolated to infinity determined from the concentration at the last 
measurable time point divided by the kel 


 
 
Propylene Glycol-Free Melphalan 200 
 
16 
 
Statistical 
Procedures 
(continued) 
The plasma concentrations and PK parameters for Melphalan HCl for injection 
(propylene glycol free) will be summarized using descriptive statistics:  arithmetic 
means, standard deviations and coefficients of variation will be calculated for all PK 
parameters and geometric means calculated for AUC0–t, AUC0–∞ and Cmax..   
Efficacy Analyses 
Rates of TRM, myeloablation and engraftment will be summarized descriptively.  
Efficacy analysis will be performed on the enrolled patients.  Time to myeloablation 
and engraftment will be summarized using Kaplan-Meier estimates. 
Myeloma Response Analyses 
Myeloma specific response for each patient will be evaluated between days 90 – 100 
after transplant, using uniform response criteria (IMWG). Responses for the patients 
will be summarized, using response rates stratified by depth of response. 
 
Safety Analyses 
Safety analyses will be performed on the population. These include any patient who 
received at least one dose of study medication.  The following safety analyses will be 
performed for this study and will include all collected data through the final study visit: 
• 
Incidence of all treatment-emergent AEs and drug-related treatment-emergent AEs 
by system organ class and preferred term. 
• 
Incidence of all treatment-emergent AEs by system organ class, preferred term and 
severity. 
• 
Incidence of all treatment-emergent AEs and treatment-emergent drug-related AEs 
by CTCAE v4.0 grade.  
• 
Incidence of treatment-emergent AEs, treatment-emergent drug-related AEs and 
treatment-emergent CTCAE v4.0 Grade 3 or 4 AEs by preferred term in 
descending frequency. 
• 
Incidence of all AEs that led to discontinuation of study medication. 
• 
Incidence of acute propylene glycol toxicities (metabolic acidosis and lactic 
acidosis). 
• 
Incidence of all SAEs and drug-related SAEs, including deaths. 
• 
Summary of changes in laboratory parameters from baseline to postdose time 
points. 
• 
Laboratory parameters summarized by CTCAE v4.0 Grade (frequency and shifts). 
• 
Summary of vital sign changes in vital signs from baseline to postdose time points. 
 
 
 


 
 
Propylene Glycol-Free Melphalan 200 
 
17 
 
2 LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
AE 
adverse event 
ANC 
absolute neutrophil count 
ANOVA 
analysis of variance 
ASBMT 
American Society for Blood and Marrow Transplantation 
ASCT  
autologous stem cell transplant 
AUC0–t 
area under the plasma concentration time curve to the last measurable time point 
AUC0–∞  
area under the plasma concentration time curve extrapolated to infinity 
ß-HCG 
beta human chorionic gonadotropin 
BSA 
 
body surface area 
BUN  
blood urea nitrogen 
CBC  
complete blood count 
Cmax 
 
maximum concentration 
CFR 
 
Code of Federal Regulations 
CMV  
cytomegalovirus 
CPK 
 
creatine phosphokinase 
CRF 
 
case report form 
CRO  
contract research organization 
DLCO  
carbon monoxide diffusing capacity 
EBV  
Epstein-Barr virus 
ECG  
electrocardiogram 
ECOG  
Eastern Cooperative Oncology Group 
FACT  
Foundation for the Accreditation of Cellular Therapy 
FDA  
Food and Drug Administration 
FEV1 
 
forced expiratory volume in one second 
FVC 
 
forced expiratory vital capacity 
GCP 
 
Good Clinical Practice 
HDC  
high dose chemotherapy 
HIPAA 
Health Insurance Portability and Accountability Act 
HIV 
 
human immunodeficiency virus 
HSV  
herpes simplex virus 
HTLV1 
human T-lymphotropic virus 


 
 
Propylene Glycol-Free Melphalan 200 
 
18 
 
IBW 
 
ideal body weight 
ICF 
 
informed consent form 
ICH 
 
International Conference on Harmonization 
IRB 
 
institutional review board 
kel 
 
elimination rate constant 
LD50  
median lethal dose 
LDH  
lactic dehydrogenase 
LV 
 
left ventricular 
MedDRA 
Medical Directory for Regulatory Activities  
MM 
 
multiple myeloma 
MRI 
 
magnetic resonance imaging 
MUGA 
multigated acquisition scan 
NCCN  
National Comprehensive Cancer Network  
NCI-CTC 
National Cancer Institute Common Toxicity Criteria 
PK 
 
pharmacokinetic 
RBC  
red blood cell 
RPR 
 
rapid plasma regain 
SAE 
 
serious adverse event 
SAP 
 
statistical analysis plan 
SGOT  
serum glutamic oxaloacetic transaminase 
SGPT  
serum glutamic pyruvic transaminase 
Tmax 
 
time to maximum concentration  
t1/2 
 
half life 
TBI 
 
total body irradiation 
ULN  
upper limit of normal 
WBC  
white blood cell 
WNV  
West Nile Virus 
TRM  
Transplant related mortality 
 


 
 
Propylene Glycol-Free Melphalan 200 
 
19 
 
3 INTRODUCTION 
3.1 Background 
Melphalan is an antineoplastic agent formulated for parenteral use as a sterile, nonpyrogenic, 
freeze-dried powder.  It is manufactured by Cardinal Health for GlaxoSmithKline and distributed 
by Celgene as Alkeran for injection (Alkeran).  Spectrum Pharmaceuticals, Inc. (Spectrum), 
developed  Melphalan Hydrochloride (HCl) for injection (propylene glycol free), a reformulation 
of Alkeran that incorporates the Captisol® brand of β-cyclodextrin sulfobutyl ether and sodium 
salts (also known as (SBE)7m-β-CD) into the freeze-dried product.  Captisol® is present to 
facilitate the use of an aqueous diluent (normal saline) for reconstituting the freeze-dried product 
instead of the cosolvent diluent necessary for the reconstitution of Alkeran, and Captisol® 
improves stability, allowing for longer infusion times. 
A major concern with melphalan therapy, other than its intrinsic cytotoxicity and 
biocompatibility, arises from its marginal solubility and limited chemical stability upon 
reconstitution and dilution.  Cosolvents are used in the marketed two-vial formulation, which is 
believed to contribute to therapy side effects.  The commercially available lyophilized 
formulation of melphalan is marketed in a single-dose vial that contains melphalan hydrochloride 
equivalent to 50 mg melphalan and 20 mg povidone.  The product is reconstituted with a sterile 
cosolvent diluent, containing propylene glycol and ethanol, by rapidly injecting 10 mL of diluent 
directly into the vial of lyophilized powder, and then, shaking immediately and vigorously until a 
clear solution is obtained.  Following these steps exactly is important for proper reconstitution.  
The resulting solution (at 5 mg/mL) must then be immediately further diluted to a concentration 
not greater than 0.45 mg/mL with normal saline in order to deliver the proper dose.  Intravenous 
administration (in a minimum of 15 minutes) of the fully diluted product (110 mL) must be 
completed within 60 minutes of reconstitution due to instability of the solution (a citrate 
derivative of melphalan can form in as little as 30 minutes).  Additionally, upon further dilution 
with normal saline, nearly 1% of the labeled strength of melphalan hydrolyzes every 10 minutes.  
Furthermore, reconstituted Alkeran  solutions cannot be refrigerated because a precipitate may 
form when the solutions are stored at 5 degrees Celsius (ºC). 
The solubilizing agent used in intravenous Alkeran is propylene glycol, which is also used as a 
solubilizing excipient in other water insoluble drugs.  Propylene glycol at high doses has been 
reported to cause renal dysfunction, hyperosmolality, increased anion gap metabolic acidosis, 
and sepsis-like syndrome (Zar, 2007; Wilson, 2005; Yaucher, 2003).  It has been reported that 
propylene glycol injected at doses above 69 g/day may produce toxicities.  Propylene glycol is 
metabolized rapidly in the body, so it is also believed that the propylene glycol toxicity is related 
to intravenous infusion rate. Therefore, the maximum recommended infusion rate of propylene 
glycol is 2.9 g/h.  Propylene glycol in Alkeran is greater than 6 g per 50 mg Alkeran.  A 
typical dose of Alkeran (200 mg/m2) contains 24 g/m2 propylene glycol.  This dose of Alkeran 
would include a propylene glycol dose of about 45 g for a 70-kilogram (154-pound) patient.  If 
this Alkeran dose is infused into the body for myeloablative conditioning in as little time as 
15 minutes, as limited by the product stability after reconstitution, then the propylene glycol 
infusion rate is very high at 180 g/h, or nearly 60 times faster than the recommended rate. 


 
 
Propylene Glycol-Free Melphalan 200 
 
20 
 
Melphalan HCl for injection (propylene glycol free) is formulated as a sterile, nonpyrogenic, 
freeze-dried cake (made from melphalan hydrochloride and containing Captisol®  in place of 
povidone) to be reconstituted initially with normal saline and either used piggyback or further 
diluted with normal saline for intravenous administration.  The substitution of Captisol®  in 
Melphalan HCl for injection (propylene glycol free) for the excipients found in Alkeran directly 
overcomes the formulation limitations (such as the final concentration of 0.45 mg/ml for 
Alkeran) and provides a potentially safer melphalan formulation for administration at the high 
doses used in the myeloablative conditioning regimens.  Moreover, Melphalan HCl for injection 
(propylene glycol free) has been shown to be stable for 10 to 24 hours once reconstituted. It may 
be refrigerated (which extends the use time). 
3.2 Nonclinical Experience  
Melphalan 
Spectrum conducted one nonclinical study to support the use of Melphalan HCl for injection 
(propylene glycol free).  The only difference between the Alkeran for injection formulation and 
the proposed Melphalan HCl for injection (propylene glycol free) is Captisol®. Therefore, the 
pharmacokinetics (PK) of melphalan were evaluated following intravenous administration in 
Sprague-Dawley® rats of a nominal 2 mg/kg melphalan dose prepared in either a Captisol®  or 
non-Captisol®  (propylene glycol) formulation.  There were no significant differences in the 
mean whole-blood and plasma AUC profiles or in the urinary excretion of melphalan following 
intravenous administration, suggesting that the change from a propylene glycol to Captisol® 
formulation does not affect melphalan PK. 
Melphalan is an older drug with a history of clinical use since the 1960s.  Approved labeling for 
both the oral and intravenous formulations of melphalan (Alkeran) support the relatively low 
clinical doses of melphalan used in multiple cycles of induction chemotherapy for MM.  While 
Alkeran for injection has not been approved for high-dose (200 mg/m2 or 100 mg/m2/day for 
two days) conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation, it 
has been successfully used and is the standard of care in the clinic for this indication.  The 
nonclinical data in the paragraphs below are excerpted from the current Alkeran labeling.   
Melphalan is a bifunctional (interstrand and intrastrand) alkylating agent that is non-cell-cycle 
specific.  Melphalan is actively transported into cells by the high-affinity L-amino acid transport 
system.  It exerts an intracellular cytotoxic effect through the formation of interstrand or 
intrastrand DNA cross-links or DNA-protein cross-links via the two chlorethyl groups of the 
molecule (alkylation), which leads to impairment of DNA replication and mitotic division and 
eventually cell death.  Like other bifunctional alkylating agents, it is active against both resting 
and rapidly dividing tumor cells. 
Melphalan acute toxicity following intravenous administration was evaluated in the rat and 
following oral and intraperitoneal administration in mouse and rat.  The intravenous median 
lethal dose (LD50) was determined to be 5.1 and 6.6 mg/kg in male and female rats, respectively.  
These doses are equivalent to 30.6 and 39.6 mg/m2 in the male and female rat, respectively, 
indicating that in animal studies melphalan cannot be administered at doses high enough to 
support melphalan high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell 


 
 
Propylene Glycol-Free Melphalan 200 
 
21 
 
transplantation in humans.  Melphalan has been shown to cause chromatid or chromosome 
damage in humans and was considered to be carcinogenic because chronic administration by 
intraperitoneal injection produced lymphosarcomas and dose-related increase in lung tumors in 
mice and peritoneal tumors in rats.  Melphalan was embryolethal and teratogenic in rats 
following oral and intraperitoneal administration.  It has been reported that Alkeran for 
injection may cause local tissue damage should extravasation occur, and melphalan was 
determined to be a mild irritant following topical application. 
The acute LD50 and chronic administration data indicate that nonclinical species demonstrate 
toxicity consistent with that seen in humans but at lower doses.  Nonclinical studies could not be 
conducted at dose levels equivalent to the anticipated daily human dose of 100 mg/m2, based on 
the observed intravenous LD50 values of 5.1 and 6.6 mg/kg (equivalent to 30.6 and 39.6 mg/m2) 
in male and female rats, respectively.  The primary dose-limiting toxicity of therapy relates to the 
myeloablative pharmacological effect of melphalan — the desired pharmacological activity in 
the clinical patient population.  The high-dose melphalan clinical data found in the public 
domain support the conduct of well-controlled clinical trials with melphalan for high-dose 
conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients 
with MM.  
Captisol® 
Captisol® is the major excipient in the Melphalan HCl for injection (propylene glycol free) 
formulation.  There was no mortality or other evidence of toxicity observed in the single-dose 
intravenous toxicity studies in which 2,000 mg/kg Captisol® was administered over 10 or 
20 seconds in the mouse and rat, respectively.  In repeat-dose toxicity studies, vacuolation of 
renal tubular epithelium cells was observed in rats, dogs, and monkeys.  This type of vacuolation 
is commonly seen in animals given substituted ß-cyclodextrins.  There was no evidence of 
degeneration, necrosis or pseudocrystal formation in the epithelial cells at doses 
1,000 mg/kg/day for one month in rats, 1,500 mg/kg/day for one month in dogs or 
5,600 mg/kg/day for 14 days in monkeys.  There was no evidence to suggest a deterioration of 
renal function, and vacuolation was largely reversible.  There was no evidence of mutagenicity 
and no effects on the reproductive function of rats or rabbits were observed in the studies 
conducted with Captisol®.  In conclusion, intravenous toxicity studies with Captisol®  doses as 
high as 1,000 mg/kg/day (equivalent to 6000 mg/m2/day) in rats, 1,500 mg/kg/day (equivalent to 
30,000 mg/m2/day) in dogs and 5,600 mg/kg/day (equivalent to 67,200 mg/m2/day) in monkeys 
did not produce toxicologically significant findings suggestive of a risk to humans.  The 
recommended dose for the Melphalan HCl for injection (propylene glycol free) is 200 mg/m2, 
which is equivalent to 5,400 mg/m2/day, based on a 70-kilogram patient with a BSA of 1.8 m2). 
3.3 Previous Clinical Experience  
Melphalan 
Melphalan is an alkylating chemotherapeutic agent that has been used alone or in combination 
with other drugs in the treatment of MM.  For decades, the mainstay of therapy for MM has been 
oral chemotherapy with melphalan plus prednisone.  Subsequently, the discovery that high-dose 
chemotherapy (HDT), coupled with ASCT, could overcome tumor resistance and prolong 


 
 
Propylene Glycol-Free Melphalan 200 
 
22 
 
survival compared with conventional chemotherapy led to the routine incorporation of HDT,  as 
part of the front-line treatment of patients early in the disease course or at the time of relapse  
(Attal, 1996).  Treatment regimens have included intravenous infusion of melphalan at doses 
ranging from 140 to 220 mg/m2, often combined with total body irradiation (TBI) or other 
chemotherapeutic agents, followed by stem cell rescue. 
During the past 10 years, MM treatment has evolved into a two-stage treatment approach.  The 
first stage consists of induction therapy, consisting of conventional chemotherapy in a variety of 
combinations (Kyle, 2004).  The goal of the first therapy stage, in patients eligible for transplant, 
is to maximize the number of healthy stem cells that can be collected; therefore, alkylating 
agents (such as melphalan) are avoided.  Following conclusion of the first stage (usually multiple 
treatment cycles), peripheral blood stem cells are collected from the patient and the second 
treatment stage is initiated (NCCN, 2015; Kyle, 2004). 
The second stage consists of consolidation treatment with HDT, followed by ASCT for selected 
patients.  The most commonly used HDT agent is intravenous melphalan, which is termed a 
conditioning agent in this context (Bensinger, 2008; Facon, 2007; Niesvizky, 2008).  The second 
stage goal is to maximize myeloablation, while providing ASCT to reduce the hematological 
toxicity of the conditioning agent.  This two-stage HDT-ASCT treatment approach is a Category 
1 recommendation by the National Comprehensive Cancer Network (NCCN, 2015).  The 
American Society for Blood and Marrow Transplantation (ASBMT) also recommends the HDT-
ASCT approach for newly diagnosed MM patients, based on consensus reached by an expert 
panel, following an evidence-based literature review (Hahn, 2003, Shah et al 2015).  Patients, 
who are not candidates for transplant due to poor performance status or 
comorbidities/complications, continue to receive induction agents, as appropriate.  This 
evolution in MM treatment has led to clinically relevant improvements in responses during the 
last decade (Bensinger, 2008; Kumar, 2008; Kyle, 2008; Pant, 2007). 
Because Alkeran is only approved at lower doses (16 mg/m2), the data from the Alkeran label 
are not always relevant to the use of high-dose melphalan; however, the major toxicities are 
expected to be similar for both the high- and low-dose uses of melphalan.  The major acute 
toxicities associated with melphalan treatment are related to bone marrow suppression, 
hypersensitivity reactions, gastrointestinal toxicities, and pulmonary toxicity.  The major long-
term side toxicities are related to infertility and secondary malignancies (Alkeran for Injection 
PI, 2008) 
Safety data regarding a single high-dose treatment of melphalan (doses ranging from 140 to 
220 mg/m2), followed by ASCT, are not fully described in the literature, because high-dose 
melphalan toxicities are well-understood among transplant physicians.  A number of studies 
designed to assess the efficacy of high-dose melphalan,  followed by autologous bone marrow 
transplant or ASCT, have included information regarding dose-limiting toxicities but not 
necessarily information about common adverse effects.  These clinical studies showed that an 
increasing melphalan dose results in a better response; however, with increasing the dose, there 
is an increasing incidence and severity of side effects (Moreau, 1999; Kühne, 2007).  
Despite blood or marrow stem cell rescue, myelosuppression with neutropenia and 
thrombocytopenia occur in all patients (Moreau, 1996; Sarosy, 1988).  Both the severity and 


 
 
Propylene Glycol-Free Melphalan 200 
 
23 
 
duration of myelosuppression are dose dependent.  Gastrointestinal toxicity is the major 
nonhematological toxicity of high-dose melphalan and includes mucositis, nausea, vomiting and 
diarrhea.  Although melphalan doesn’t appear to be cardiotoxic like other alkylating agents, atrial 
fibrillation has been reported after high-dose melphalan administration, particularly in elderly 
patients who are prone to atrial fibrillation.  In addition, pulmonary toxicities, such as pulmonary 
fibrosis, are a rare and late complication of melphalan therapy. 
Melphalan HCl for injection (propylene glycol free) has been studied in humans in two studies to 
date. The Phase II, open-label study was the only one where 200 mg/m2 dose of Melphalan HCl 
for injection (propylene glycol free) was administered to MM patients (Hari 2015). This study 
enrolled  61 MM patients, who received 200 mg/m2 of CE-Melphalan (100 mg/m2/day x 2) 
followed by ASCT. The majority of the subjects were male (57%) with a median age of 62.0 
years (range 32-73), and included 56 (92%) subjects receiving upfront AHCT and five (8%) after 
relapse. Median lines of prior therapy were three (range 2-16). All subjects achieved 
myeloablation, followed by successful engraftment. Median time to neutrophil engraftment was 
12 days postAHCT (range: 10–12); time to platelet engraftment was 13 days (range 10–28). 
There was no mortality by day 100, and as expected the most common Grade 3 and 4 toxicities 
were hematologic. Severe mucositis was reported in few patients (Grade 3/4; 10%).  At day 100 
postAHCT, all patients (100%) had a response with 82% of subjects achieving a >= very good 
partial response (VGPR) response, including stringent CR in 13%, CR in 8% and VGPR in 61%. 
Notably, the dosage schema reported did not use the more common approach of a single infusion 
of melphalan of 200 mg/m2. 
 
Captisol® 
Captisol® is currently used in four approved human parenteral products in the United States.  
Exposure data from FDA-approved package inserts for these products are summarized in  
Table 1. 


 
 
Propylene Glycol-Free Melphalan 200 
 
24 
 
 
Table 1. 
FDA-Approved Drug Products Containing Captisol® 
 
Drug Product 
Indication 
Route 
Captisol®  Concentration 
Captisol®  Exposure 
 
In Drug 
Product 
For Dosing 
Maximum Rate 
of Intravenous 
Infusiona 
Maximum 
Total Daily 
Dose 
(Duration) 
 
VFEND® I.V. 
Treatment of 
fungal 
infections 
iv 
160 mg/mL 
(after 
reconstitution) 
80 mg/mL 
(after 
dilution) 
56 mg/minb 
(over 1–2 h) 
192 mg/kg  
(Day 1), then 
128 mg/kg 
(maintenance 
dosingc) 
 
NEXTERONE® 
Injection 
Acute 
treatment of 
ventricular 
arrhythmias  
iv 
225 mg/mL 
6.55 mg/mL 67.5 mg/min 
(for 10 min; 
initial loading 
dose)d 
68 mg/kg 
(over first 24 h 
of therapy, then 
repeat as needed 
for up to 
3 weeks) 
 
GEODON® 
Injection 
Acute agitation 
in 
schizophrenia 
im 
294 mg/mL 
(after 
reconstitution) 
294 mg/mL  NA 
8.4 mg/kg  
(NMT 3 days) 
 
ABILIFY® 
Injection 
Acute agitation 
in 
schizophrenia 
or bipolar 
mania 
im 
150 mg/mL 
150 mg/mL NA 
8.6 mg/kg  
(Day 1) 
 
a 
= 
Based on an average patient (e.g., weight = 70 kilogram, BSA = 1.8 m2). 
 
b 
= 
Equivalent to 48 mg/kg/h for a 70-kilogram patient. 
 
c 
= 
Duration of therapy, based on disease severity, recovery from immunosuppression and clinical 
response. 
 
d 
= 
Followed by additional infusions at lower rates. 
 
NMT = 
Not more than. 
 
 
Based on the concentration of Captisol® contained in these marketed products, the amount of 
Captisol® contained in the Melphalan HCl for injection (propylene glycol free) is comparable to 
the amount of Captisol® administered in these approved products on a daily basis.  Captisol® has 
also been administered intravenously to humans in investigational products at infusion rates 
greater than those expected with Melphalan HCl for injection (propylene glycol free). 
3.4 Rationale for Study and Dose Selection 
Currently, the higher doses of melphalan being used in ASCT patients are not approved by FDA; 
however, they have been used off label for this purpose for a number of years.  The current 
commercial formulation of Alkeran for injection has been used for HDT but has several 
limitations, based on marginal solubility. These prevent the solution from being administered as 
a longer infusion and are believed to contribute to therapy side effects.  The commercial product 
must be reconstituted with a sterile diluent that contains propylene glycol, a substance that has 
been associated with certain side effects.  After reconstitution, an impurity (citrate derivative of 


 
 
Propylene Glycol-Free Melphalan 200 
 
25 
 
melphalan) can develop in less than 30 minutes and, when further diluted, melphalan’s potency 
is lost over time.  
The substitution of Captisol® in Melphalan HCl for injection (propylene glycol free) for the 
excipients found in Alkeran for injection directly overcomes these formulation limitations.  
Captisol® is a substituted ß-cyclodextrin that serves as the major functional excipient in 
Melphalan HCl for injection (propylene glycol free).  Captisol® performs as a solubilizing and 
stabilizing agent by forming reversible complexes with melphalan in the formulation.  When the 
formulation is administered intravenously, the complex rapidly dissociates due to its dilution by 
blood and the distribution and binding of melphalan to body tissues and blood components. 
This study is being conducted as a Phase II, PK study of Melphalan HCl for injection (propylene 
glycol free) for myeloablative conditioning in MM patients undergoing autologous 
transplantation.  It is anticipated that this study’s PK data will be used define the PK-directed 
dosing for Melphalan HCl for injection (propylene glycol free). There has only been one large-
population pharmacokinetic study on melphalan pharmacokinetics in patients with multiple 
myeloma receiving HDM (Nath 2010). This study used a standard melphalan preparation 
(Alkeran) and not the propylene glycol-free product studied in this protocol.  Factors that were 
found to be important determinants of clearance of melphalan included creatinine clearance, fat-
free mass and hematocrit. Importantly, total and unbound melphalan exposure had significant 
associations with melphalan-related transplant toxicity and myeloma response to transplant.  
Patients, who achieved an overall deep-disease response of CR or VGPR, had significantly (P < 
0.05) higher unbound AUC than those who did not. There is considerable variability in 
melphalan pharmacokinetics and current knowledge of its pharmacodynamics is very limited 
(Shaw 2014). The current study will establish the PK this new melphalan formulation in order to 
establish a safe and effective conditioning therapy platform.  
The doses of study drugs selected for this study (200 mg/m2 of Melphalan HCl for injection 
[propylene glycol free] on day -2) was chosen, based on current clinical practice of melphalan 
(Alkeran) dosing among transplant physicians.  The study drug will be infused over 30 min via 
a central venous catheter during this study, thus allowing for a PK comparison valid based on 
current clinical practice. 
3.5  Rationale for Autologous Transplant; Myeloablation 
Based on published data, 100% of all patients receiving Propylene Glycol-Free Melphalan HCl 
at a dose of 200 mg/m2 achieve myeloablation (Harr, 2015). In fact myeloablation is universal in 
patients receiving this drug dose. The reason autologous stem cells are used after this treatment is 
because irreversible myeloablation follows this dose.  
The rationale for autologous transplant itself is to utilize the steep dose-response curve of tumors 
to cytotoxic therapy, i.e., small increments in dose of drug or radiation markedly increase the 
number of cancer cells killed. Effective disease control depends on delivering intensive doses of 
chemotherapy and/or radiation therapy. This intensity often exceeds the tolerance of bone 
marrow, necessitating restoration of hematopoietic marrow function in patients receiving such 
high-dose therapy (HDT), to prevent irreversible and fatal myeloablation. This is accomplished 
by restoring blood production, using autologous (“self”) cells (i.e. autologous HCT).  Thus,   


 
 
Propylene Glycol-Free Melphalan 200 
 
26 
 
myeloablation is a side effect of the dose administered and in fact is an undesirable aspect in one 
sense. Therefore, we do not have lack of myeloablation as a futility measure. In fact, if myeloma 
control could be achieved without myeloablation, such treatment would not require autologous 
cell support. Finally, a melphalan product that allows patients to recover with shorter period of 
myeloablation but with similar anti MM effect, would be a significant improvement, because the 
shorter myeloablation period will be safer for the patient. (Hari, 2014) 
The equivalent bioavailability of standard melphalan and PG free Melphalan has been 
established and since standard melphalan at 200 mg/m2 causes myeloablation universally, we 
expect PG free Melphalan to do the same.  
4 STUDY OBJECTIVES 
4.1 Objectives 
4.1.1 
Primary Objective 
This study’s primary objective is to assess the PK of Melphalan HCl for injection (propylene 
glycol free) when administered as single 200 m/m2 dose in MM patients undergoing ASCT. 
4.1.2 
Secondary Objective(s) 
This study’s secondary objectives are: 
• 
To determine the rates of complete response (CR) at day 100 of MM patients receiving 
Melphalan HCl for injection (propylene glycol free) at a single dose of 200 mg/m2. 
• 
To determine the TRM, myeloablation and subsequent neutrophil engraftment in MM patients 
receiving high-dose Melphalan HCl for injection (propylene glycol free), followed by ASCT. 
• 
To describe the overall safety of Melphalan HCl for injection (propylene glycol free) at a single 
dose of 200 mg/m2. 
4.2 Study End Points 
4.2.1 
Primary End Point 
This study’s primary end point is to define PK data for Melphalan HCl (propylene glycol free) 
when administered as a single 200 mg/m2 dose in MM patients undergoing ASCT.   
4.2.2 
Secondary End Points 
4.2.2.1 
CR Rates, TRM, Myeloablation and Engraftment 
The following efficacy end points will be measured in this trial:   
 
• MM response rates between days 90–100 after ASCT (IMWG Uniform Response 
Criteria; Appendix I). 
• Treatment-related mortality (death within 100 days without relapse). 


 
 
Propylene Glycol-Free Melphalan 200 
 
27 
 
• Myeloablation rate during the study 
• Engraftment rate during the study 
• Time to myeloablation 
• Time to engraftment 
 
These end points will be measured through collection of hematology parameters (CBC with 
differential) daily until neutrophil engraftment. 
 
4.2.2.2 
Safety Assessments 
Safety assessments will include:  SAEs, AEs, vital signs, clinical laboratory assessments 
(hematology, serum chemistry, urinalysis, creatinine clearance, physical examination findings, 
ECOG performance status).   
 


 
 
Propylene Glycol-Free Melphalan 200 
 
28 
 
5 STUDY DESIGN 
5.1 Overall Study Design and Plan 
This study will be a single center, open-label, study of high-dose Melphalan HCl for injection 
(propylene glycol free) in 24 patients, who have symptomatic MM and qualify for ASCT. 
There will be three distinct evaluation periods in this trial:  a pretreatment period, a study period, 
and a follow-up period.   
5.1.1 
Pretreatment Period (Day -30 to Day -3) 
The pretreatment period will include collection and recording of baseline assessments.  The 
baseline assessments will include physical examination; ECOG performance status; infectious 
disease testing (serum titers for CMV, HSV, EBV, WNV, RPR for syphilis, hepatitis panel, and 
HIV and HTLV1 antibodies); clinical laboratory tests (hematology, serum chemistry); chest X-
ray; vital signs, including height, weight, and BSA; and any transplant-related tests that ensure 
that the patient has adequate organ function.   
5.1.2 
Study Period (Day -2 to Day 0) 
During the study period, patients will receive 200 mg/m2 of Melphalan HCl for injection 
(propylene glycol free) day -2.  Blood samples for PK evaluation will be withdrawn through an 
indwelling intravenous cannula the day of melphalan dosing (day -2).  (Blood samples for PK 
analysis should not be drawn from the same IV line used  to administer the melphalan.) 
Following one day of rest after the myeloablative conditioning (day -1), patients will receive an 
autologous graft with a minimum cell dose of 2 × 106 CD34+ cells/kg of patient body weight 
(Day 0).  Cryopreservation and thawing of product will be consistent with FACT standards and 
local institutional practice.  The graft will be infused per institutional protocol.   
During the study period, postdose vital signs and laboratory assessments (electrolyte panel, 
BUN, creatinine, liver function panel) will be taken on day -2 to monitor for propylene glycol-
related toxicities.   
5.1.3 
Follow-up Period (Day +1 to day+100) 
During the follow-up period, patients will return for daily laboratory tests (basic chemistry and 
hematology panels) and will be evaluated weekly by their physician until the date of 
engraftment, with the final end-of-study evaluation occurring up to seven days after the date of 
engraftment.  
Filgrastim or pegfilgrastim will be administered as described in Section 7.7.2.  Engraftment is 
defined per CIBMTR criteria (Section 8.3.2.1.)  All patients will receive antiemetics, hydration 
and infection prophylaxis according to institutional guidelines.  Weekly safety assessments 
(physical examination findings, ECOG performance status, AEs/SAEs, vital signs, hematology, 
serum chemistry) will be taken until the patient has achieved engraftment. After engraftment, the 
patient will be followed every 2 weeks with CBC and every 4 weeks with multiple myeloma 


 
 
Propylene Glycol-Free Melphalan 200 
 
29 
 
panel. Bone marrow biopsy and multiple myeloma panel will be done at day +100 to assess the 
post transplant disease evaluation. 
5.2 Study Schema 
The following study schema summarizes the treatment design for the three evaluation periods. 


 
 
Cydex Pharmaceuticals, Inc.  
CDX-353-001 
 
Melphalan HCl for Injection (Propylene Glycol-Free) 
 
PRO AME 16150 IIT HARI MEL SPEC Protocol VERSION 11 02-20-2016 
30 
Confidential 
 


CONFIDENTIAL 
 
Cydex Pharmaceuticals, Inc.  
CDX-353-001 
 
Melphalan HCl for Injection (Propylene Glycol-Free) 
 
31 
 
5.3 Stopping Rules 
High dose therapy and cell transplantation is associated with hospitalization and risk of treatment 
related mortality. As such, grade 3-4 non hematological toxicities are expected in this program, 
similar to standard of care autologous transplantation. Modern published data on treatment 
related mortality has ranged from 1-4%. The data and safety monitoring committee (dsmc) will 
have authority to stop study for any unexpected treatment related mortality events during the 
entire course of the study. In the event of adverse events leading to treatment related mortality in 
3 or more (out of 24) patients treated at phase 2 dosing, the study will be suspended. The dsmc 
will also be asked to review all non-hematologic grade 4-5 events and make a final determination 
of safety. See section 11.6.1 for more details. 
 
6 SELECTION AND WITHDRAWAL OF SUBJECTS 
6.1 Inclusion Criteria 
• Patients with symptomatic MM requiring treatment at or following diagnosis. 
• Patients with MM, who qualify for ASCT therapy, and have received pretransplant therapy 
prior to transplantation. 
• Adult patients (≥18 years of age) meeting local institutional criteria to receive a total 
Melphalan dose of 200 mg/m2 as a conditioning regimen.  
• Patients with an adequate autologous graft, which is defined as an unmanipulated, 
cryopreserved, peripheral blood cell graft containing at least 2 × 106 CD34+ cells/kg, based 
on patient’s actual body weight.  
• Patients with adequate organ function, as measured by: 
 Cardiac:  Left ventricular ejection fraction at rest >40% (documented within 30 days 
prior to Day -3). 
 Hepatic:  Bilirubin <2 × ULN and ALT/AST <3 × ULN. 
 Renal:  Creatinine clearance >40 mL/min (measured or calculated/estimated). 
 Pulmonary:  Adjusted DLCO, FEV1, FVC >50% of predicted value (corrected for Hgb) 
and documented within  prior to day -3. 
6.2 Exclusion Criteria 
• Patients with systemic AL amyloidosis. 
• ECOG performance status ≥2. 
• Patients with uncontrolled hypertension. 
• Patients with a serious active bacterial, viral or fungal infection. 
• Patients with prior malignancies except resected basal cell carcinoma or treated cervical 
carcinoma in situ.  Cancer treated with curative intent >5 years previously will be allowed.  


CONFIDENTIAL 
 
Cydex Pharmaceuticals, Inc.  
CDX-353-001 
 
Melphalan HCl for Injection (Propylene Glycol-Free) 
 
32 
 
Cancer treated with curative intent <5 years previously will not be allowed unless approved 
by the medical monitor. 
• Female patients who are pregnant (positive ß-HCG) or breastfeeding. 
• Female patients of childbearing potential, who are unwilling to use adequate contraceptive 
techniques during and for one month following study treatment with Melphalan HCl for 
injection (propylene glycol free). 
• Patients seropositive for HIV. 
• Concurrent clinical trials for post-transplant therapy of myeloma are permitted provided such 
studies do not involve conditioning therapy 
• Patients who are unwilling to provide informed consent. 
• Patients who are hypersensitive or intolerant to any component of the study drug formulation. 
• Prior ASCT (tandem ASCT) is not permitted. Only single autologous transplant is allowed.  
6.3 Withdrawal Criteria 
The subject has the right to withdraw from the study at any time. 
The subject will be withdrawn from the study if: 
• There is deterioration in the subject’s signs/symptoms and/or the subject develops a disease 
or condition that, in the opinion of the Investigator, would compromise the subject’s safety 
by continuing in the study. 
• In the investigator’s judgment, it is in the subject’s best interests. 
• There is a violation of the protocol inclusion and exclusion criteria as deemed relevant by the 
investigator and discussed with the investigator. 
• The subject begins to take any medication(s) that is excluded by the protocol. 
• Any of the conditions are met in Section 5.3, “Stopping Rules.” 
If a subject withdraws prematurely from the trial due to the above criteria or any other reason, 
study staff should make every effort (at withdrawal) to complete the full set of evaluations 
scheduled for the end-of-study evaluation.  The reason for subject withdrawal must be 
documented in the CRF. 
If a subject withdraws from the study due to an AE (e.g., clinical signs, symptoms or clinically 
significant laboratory abnormality), the subject will be asked to return to the clinic for the 
evaluations scheduled for the posttreatment follow-up period, at a minimum.  If the AE has still 
not resolved, additional follow-up will be performed, as appropriate, and documented in the 
subject’s medical records.  As a minimum requirement, AEs should be followed for seven days 
after the date of engraftment or until any treatment-emergent AE or laboratory abnormality has 
resolved or is otherwise explained. 


CONFIDENTIAL 
 
Cydex Pharmaceuticals, Inc.  
CDX-353-001 
 
Melphalan HCl for Injection (Propylene Glycol-Free) 
 
33 
 
In the case of a subject lost to follow-up, attempts to contact the subject must be made and 
documented in the subject’s medical records. 
Withdrawn subjects will not be replaced. 


CONFIDENTIAL 
 
Cydex Pharmaceuticals, Inc.  
CDX-353-001 
 
Melphalan HCl for Injection (Propylene Glycol-Free) 
 
34 
 
7 TREATMENTS, CONCOMITANT THERAPY, AND DOSE 
MODIFICATIONS 
7.1 Treatments Administered 
During the study period, patients will receive 200 mg/m2 of Melphalan HCl for injection 
(propylene glycol free) prior to ASCT.  Melphalan HCl for injection (propylene glycol free) will 
be diluted with normal saline to a concentration of no greater than 2 mg/mL and infused over 30 
minutes via a central venous catheter.  For the calculation of BSA, actual body weight should be 
used for patients, who weigh less than or between 100 and 130% of their IBW.  For patients who 
weigh more than 130% of their IBW, BSA should be calculated based on adjusted body weight.  
For calculation of body surface area, the most recent height and weight available on day -2 will 
be used. 
BSA = (W 0.425 x H 0.725) x 0.007184, where W=weight and H=height  
Adjusted body weight= IBW + 0.4(actual weight - IBW) 
Institutional standards of care rounding policies may be followed for calculating the final dose of 
melphalan. 
7.2 Identity of Study Product(s) 
7.2.1 
Investigational Product 
Melphalan HCl for injection (propylene glycol free) is a white lyophilized powder containing 
56 mg of Melphalan HCl (equivalent to 50 mg of melphalan free base) and 2,700 mg 
sulfobutylether-beta-cyclodextrin Captisol®.  There is also sodium hydroxide and hydrochloric 
acid, if necessary, present in the product that is used to adjust the pH of the solution prior to 
lyophilization to a physiologically well-tolerated range of pH 5.0 ± 1.0.   
Normal saline solution (0.9% sodium chloride injection, USP) is used to reconstitute (8.6 mL) 
and dilute (for infusion) the product prior to clinical use.  After reconstitution with 0.9% normal 
saline, the concentration of the diluted vial is 5mg/mL. Immediately further dilute with 0.9% 
normal saline to a final concentration equal to 2 mg/mL. Melphalan HCl for injection (propylene 
glycol free) is stable at room temperature for at least four hours after reconstitution, if followed 
by immediate dilution.  
Melphalan HCl for injection (propylene glycol free) will be supplied in a 20 mL glass vial, Type 
I, with a 20-mm finish, a 20-mm lyophilization type rubber stopper and a crimp seal.  Melphalan 
HCl for injection (propylene glycol free) vials should be stored protected from light and at a 
controlled room temperature of 20–25 °C (68–77 °F) with excursions permitted between 15 and 
30 °C (59 and 86 °F). 
Below is an example of the information that may appear on the label of the study medication: 
• Spectrum 


CONFIDENTIAL 
 
Cydex Pharmaceuticals, Inc.  
CDX-353-001 
 
Melphalan HCl for Injection (Propylene Glycol-Free) 
 
35 
 
• Melphalan HCl for injection (propylene glycol free), lyophilized powder containing 56 mg 
Melphalan HCl (equivalent to 50 mg Melphalan free base)  
• Each vial contains Melphalan HCl, Captisol® and sodium hydroxide 
• Reconstitute with normal saline prior to infusion 
• Protocol Number IIS-MEL-MCW-001 
• Lot number 
• Manufacture date 
• Manufactured by DSM Pharmaceuticals, Inc., Greenville, North Carolina, U.S.A; for 
Spectrum Pharmaceuticals, Inc., USA 
• Storage conditions 
7.3 Assigning Subjects to Treatment Group 
All patients will receive 200 mg/m2 of either Melphalan HCl for injection (propylene glycol free) 
on day -2 prior to ASCT administered over 30±5 minutes as a 2mg/ml solution. 
7.4 Study Medication Accountability 
The investigator/pharmacist must maintain accurate records of study drug disposition, patient 
administration (including date and time), in addition to noting any accidentally destroyed drugs.  
Spectrum will supply a specific drug accountability form.  At the end of the study, information 
describing study drug supplies (e.g., lot numbers) and disposition of supplies for each patient 
must be provided, signed by the investigator. If any errors or irregularities in any shipment of 
study medication to the site are discovered at any time, Spectrum must be contacted 
immediately. 
At the end of the study, all medication not dispensed or administered and packaging materials 
will be collected with supervision of the monitor and returned to Spectrum or destroyed onsite,  
as dictated by the appropriate SOP at this institution. 
7.5 Blinding/Masking of Treatments 
This is an open-label study.  All patients enrolled in the study will receive 200 mg/m2 of 
Melphalan HCl for injection (propylene glycol free) on day -2 prior to ASCT.  No blinding or 
masking of study drug will occur. 
7.6 Treatment Compliance 
Melphalan HCl for injection (propylene glycol free) will be infused over 30±5 minutes in a 
2mg/mL solution via a central venous catheter by a trained healthcare professional.  Records of 
study medication administered (date, time, and dose administered relative to reconstitution time) 
will be recorded in the patient’s CRF.   


CONFIDENTIAL 
 
Cydex Pharmaceuticals, Inc.  
CDX-353-001 
 
Melphalan HCl for Injection (Propylene Glycol-Free) 
 
36 
 
7.7 Prior and Concomitant Therapies 
All medications used during this study must be documented in the patient CRF. 
7.7.1 
Experimental Anticancer Therapy 
No other anticancer therapies (including chemotherapy, radiation, hormonal treatment, antibody 
therapy, immunotherapy, gene therapy, vaccine therapy, angiogenesis inhibitors, matrix 
metalloprotease inhibitors or other experimental drugs) of any kind will be permitted while the 
subject is participating in the pretreatment period, study period, or follow-up period.  Other 
supportive care studies using FDA approved agents are permitted. 
7.7.2 
Hematopoietic Growth Factors 
Filgrastim  is required. Pegylated filgrastim will be administered based on institutional practice.  
For inpatient transplantation, administer filgrastim 5 micrograms/kg/day SC (may be rounded to 
the nearest vial), based on actual body weight, beginning on Day +5.  In the absence of toxicity, 
continue filgrastim until the post-nadir ANC is ≥ 500 / µL on three consecutive measurements 
over different days.  Alternatively, for outpatient transplantation, administer pegfilgrastim 6 mg 
SC once on Day + 1. 
7.7.3 
Prophylactic Treatment for Opportunistic Infections 
All patients will receive prophylaxis against bacterial, fungal and viral infections during the 
peritransplant period, according to institutional guidelines. 
7.7.4 
Antiemetics 
Patients will receive antiemetics prior to high-dose melphalan administration in accordance with 
institutional guidelines. 
7.7.5 
Antidiarrheals 
Use of antidiarrheal medications (e.g., loperamide) is permitted at the discretion of the 
investigator, but this must be documented in the CRF. 
7.7.6 
Blood Products 
Transfusion thresholds for blood product support will be in accordance with institutional 
guidelines. 
7.7.7 
Other Concomitant Medications 
Therapies considered necessary for the patient’s well-being may be given at the discretion of the 
investigator and should be documented in the CRF.  Other concomitant medications should be 
avoided except for analgesics, chronic treatments for concomitant medical conditions or agents 
required for life-threatening medical problems. 


CONFIDENTIAL 
 
Cydex Pharmaceuticals, Inc.  
CDX-353-001 
 
Melphalan HCl for Injection (Propylene Glycol-Free) 
 
37 
 
7.8 Dose Modifications for Drug-Related SAEs and/or Toxicities 
There will be no dose modifications of Melphalan HCl for injection (propylene glycol free) 
during this study. 
8 STUDY CONDUCT 
8.1 Overview of Data Collection 
The schedule of study activities is presented in Table 2. 


CONFIDENTIAL 
 
Cydex Pharmaceuticals, Inc.  
CDX-353-001 
 
Melphalan HCl for Injection (Propylene Glycol-Free) 
 
 
38 
 
; s;  
Pretreatment 
Period 
Follow-Up Period 
(Shaded Visits are Optional Visits) 
Day -30 to  
Day -3 
Day -2 
HDM 
Day -1 
Rest Day 
Day 0 
ASCT  
Daily 
Until 
Date of 
Engraft-
ment 
Week 1 
Day +7  
±2 Days 
Week 2 
Day +14  
±2 Days 
Week 3 
Day +21  
±2 Days 
Week 4 
Day +28  
±2 Days 
End-of-
Study 
Evaluation 
until day + 
100 
Informed Consent 
√ 
 
 
 
 
 
 
 
 
 
Confirm MM Diagnosis and Stage 
√ 
 
 
 
 
 
 
 
 
 
Review Entry Criteria 
√ 
 
 
 
 
 
 
 
 
 
Medical History 
√ 
 
 
 
 
 
 
 
 
 
Urine analysis 
√ 
 
 
 
 
 
 
 
 
 
Chest X-Ray 
√ 
 
 
 
 
 
 
 
 
 
Infectious Disease Screen  
√ 
 
 
 
 
 
 
 
 
 
Serum Pregnancy Testing for WCBP 
√ 
 
 
 
 
 
 
 
 
 
ECOG Performance Status  
√ 
√ 
 
 
 
√ 
√ 
√ 
√ 
√ 
Prior/Concurrent Medications 
√ 
√ 
√ 
√ 
 
√ 
√ 
√ 
√ 
√ 
AEs 
 
√ 
√ 
√ 
 
√ 
√ 
√ 
√ 
√ 
Vital Signs, Height, Weight, and BSA 
√ 
√ 
 
 
 
√ 
√ 
√ 
√ 
√ 
Physical Examination 
√ 
√ 
 
 
 
√ 
√ 
√ 
√ 
√ 
Hematology 
√ 
√ 
 
 
√ 
√ 
 
 
 
√ 
Full Serum Chemistry Panel 
√ 
√ 
 
 
 
√ 
√ 
√ 
√ 
√ 
Electrolytes, LFTs, BUN, creatinine 
 
√ 
√ 
√ 
 
 
 
 
 
 
Basic Serum Chemistry Panel 
 
 
 
 
√ 
 
 
 
 
 
Multiple myeloma panel 
 
 
 
 
 
 
 
 
 
√ 
Bone marrow biopsy 
 
 
 
 
 
 
 
 
 
√ 
PK Assessment 
 
√ 
 
 
 
 
 
 
 
 
PG free MEL 200 mg/m2 IV 
 
√ 
 
 
 
 
 
 
 
 
Autologous Stem Cell Grafta 
 
 
 
√ 
 
 
 
 
 
 
a. 
 Followed by filgrastim or pegfilgrastim support as described in Section 7.7.2.   


CONFIDENTIAL 
 
Cydex Pharmaceuticals, Inc.  
CDX-353-001 
 
Melphalan HCl for Injection (Propylene Glycol-Free) 
 
 
39 
 
8.2 Description of Study Days 
8.2.1 
Pretreatment Period (Day -30 to Day -3) 
Patient Registration: 
The patient registration will be done by the principal investigator based on the eligibility criteria 
as defined in the protocol. Any questions regarding the registration will be answered by the 
principal investigator Parameswaran Hari or the research coordinator Debra Pastorek (414-805-
6837). 
The following baseline assessments should be collected within 30 days of dosing with Melphalan 
HCl for injection (propylene glycol free), after the patient has signed the informed consent: 
• Review and confirm study entry criteria. 
• Confirm MM diagnosis and stage (using ISS criteria). 
• Medical history and physical examination, including prior MM treatments and the response. 
• Prior and concomitant medications. 
• ECOG performance status. 
• Infectious disease testing:  Serum titers for CMV, HSV, EBV, hepatitis panel, WNV, RPR 
for syphilis, HIV and HTLV1 antibodies. 
• Hematology (RBC, hemoglobin, hematocrit, platelet count, WBC with manual differential, 
and reticulocyte count). 
• Full serum chemistry panel (sodium, potassium, chloride, magnesium, bicarbonate, glucose, 
total protein, albumin, calcium, phosphate, uric acid, BUN, creatinine, total bilirubin, 
alkaline phosphatase, LDH, SGOT, SGPT and creatinine clearance).  
• Chest X-ray. 
• Urine analysis 
• Vital signs (systolic and diastolic blood pressures, heart rate, respiration rate and body 
temperature), height, weight and BSA. 
• Serum pregnancy test for women of childbearing potential.  Women are considered to be of 
childbearing potential unless they have had no menses for at least 12 months. 
• Toxicity grading and evaluation for AEs/SAEs, according to NCI-CTC AE Version 4.0 after 
signing the informed consent. 
8.2.2 
Study Period (Day -3 to Day 0) 
During the study period, patients will receive 200 mg/m2 of Melphalan HCl for injection 
(propylene glycol free) as a single intravenous dose on Day -2.  Following one day of rest after 
the myeloablative conditioning (Day -1), patients will receive an autologous graft with a 
minimum cell dose of 2 × 106 CD34+ cells/kg of patient body weight (Day 0).   


CONFIDENTIAL 
 
Cydex Pharmaceuticals, Inc.  
CDX-353-001 
 
Melphalan HCl for Injection (Propylene Glycol-Free) 
 
 
40 
 
8.2.2.1 
Day -2 
The following will be performed on day -2:  
• Full serum chemistry panel (sodium, potassium, chloride, magnesium, bicarbonate, glucose, 
total protein, albumin, calcium, phosphate, uric acid, BUN, creatinine, total bilirubin, 
alkaline phosphatase, LDH, SGOT, SGPT]) will be collected/calculated prior to dosing of 
Melphalan HCl for injection (propylene glycol free). 
• Hematology (RBC, hemoglobin, hematocrit, platelet count, WBC with manual differential, 
and reticulocyte count) will be performed prior to dosing of Melphalan HCl for injection 
(propylene glycol free). 
• Physical examination will be performed prior to dosing of Melphalan HCl for injection 
(propylene glycol free) or Alkeran for injection. 
• ECOG performance status will be recorded prior to dosing of Melphalan HCl for injection 
(propylene glycol free). 
• Body weight will be measured and BSA calculated prior to dosing of Melphalan HCl for 
injection (propylene glycol free). 
• Administration of 200 mg/m2 of Melphalan HCl for injection (propylene glycol free) in a 
2mg/mL solution over 30 minutes via a central venous catheter. 
• Blood samples of Melphalan HCl for injection (propylene glycol free) for PK evaluation will 
be withdrawn through an indwelling peripheral intravenous cannula separate from the 
infusion site at 0 (predose), 10, 20, 30, 60, 90, 120, 180, 240 minutes after the completion of 
infusion.  The predose blood sample will be collected within 60 minutes prior to 
administration of Melphalan HCl for injection (propylene glycol free). 
• Vital signs (systolic and diastolic blood pressures, heart rate, and respiration rate) will be 
recorded prior to dosing and hourly during the first four hours after receiving either 
Melphalan HCl for injection (propylene glycol free).  
• Toxicity grading and evaluation for AEs/SAEs according to NCI-CTC AE Version 4.0. 
• Concomitant medications will be recorded.  
8.2.2.2 
Day -1 
The following will be performed on day -1: 
• Hematology (RBC, hemoglobin, hematocrit, platelet count, WBC with manual differential, 
and reticulocyte count) and electrolyte panel (sodium, potassium, chloride, bicarbonate), 
BUN, creatinine. 
• Toxicity grading and evaluation for AEs/SAEs according to NCI-CTC AE Version 4.0. 
• Concomitant medications will be recorded. 


CONFIDENTIAL 
 
Cydex Pharmaceuticals, Inc.  
CDX-353-001 
 
Melphalan HCl for Injection (Propylene Glycol-Free) 
 
 
41 
 
8.2.2.3 
Day 0 
The following will be performed on Day 0: 
• Autologous graft with a minimum cell dose of 2 × 106 CD34+ cells/kg of patient body 
weight. 
• Hematology (RBC, hemoglobin, hematocrit, platelet count, WBC with manual differential, 
and reticulocyte count) and electrolyte panel (sodium, potassium, chloride, bicarbonate), 
BUN, creatinine, liver function panel (SGOT, SGPT, alkaline phosphatase and total 
bilirubin). 
• Toxicity grading and evaluation for AEs/SAEs according to NCI-CTC AE Version 4.0. 
• Concomitant medications will be recorded. 
8.2.3 
Follow-up Period (ASCT Day +1 to day+100) 
During the follow-up period, patients will return for daily laboratory tests (hematology and basic 
chemistry panel) and will be evaluated weekly by their physician until the date of engraftment, 
with the final end-of-study evaluation occurring up to seven days after the date of engraftment.   
Engraftment is defined as ANC >0.5 × 109/L × 3 consecutive daily assessments.  The date of 
engraftment is the first day of the three consecutive days that a patient’s ANC is >0.5 × 109/L. 
8.2.3.1 
Week 1 (Day +7 ± 2 Days)  
The following assessments will be performed daily until engraftment:   
• Hematology (RBC, hemoglobin, hematocrit, platelet count, WBC with manual differential, 
and reticulocyte count). 
• Basic serum chemistry panel (sodium, potassium, chloride, glucose, creatinine, bicarbonate, 
and BUN) daily until neutrophil engraftment. 
• PEG-Filgrastim may be administered according to institutional practice until ANC is 
>500 mm3. 
The following assessments will be performed at the Week 1 (Day +7 ± 2 Days) Visit:   
• Physical examination. 
• ECOG performance status.  
• Vital signs (systolic and diastolic blood pressures, heart rate, respiration rate, and body 
temperature) and body weight. 
• Full serum chemistry panel (sodium, potassium, chloride, magnesium, bicarbonate, glucose, 
total protein, albumin, calcium, phosphate, uric acid, BUN, creatinine, CPK, total bilirubin, 
alkaline phosphatase, LDH, SGOT, SGPT and creatinine clearance).  
• Toxicity grading and evaluation for AEs/SAEs according to NCI-CTC AE Version 4.0. 


CONFIDENTIAL 
 
Cydex Pharmaceuticals, Inc.  
CDX-353-001 
 
Melphalan HCl for Injection (Propylene Glycol-Free) 
 
 
42 
 
• Record concomitant medications. 
8.2.3.2 
Week 2 (Day +14 ± 2 Days), Week 3 (Day +21 ± 2 Days) and Week 4 (Day +28 ± 
2 Days) (Optional Visits Dependent on Date of Engraftment) 
The study visits at Week 2, Week 3 and Week 4 are optional visits and are dependent on the date 
of engraftment.  If a patient meets the criteria for engraftment, he or she may proceed directly to 
the end-of-study evaluation visit.  For those patients who have not met the criteria for 
engraftment, the following assessments will be performed daily until engraftment:   
• Hematology (RBC, hemoglobin, hematocrit, platelet count, WBC with manual differential, 
and reticulocyte count). 
• Basic serum chemistry panel (sodium, potassium, chloride, glucose, creatinine, bicarbonate, 
and BUN) daily until neutrophil engraftment. 
• PEG-Filgrastim may be administered according to institutional practice for neutropenia. 
For those patients who have not met the criteria for engraftment, the following assessments will 
be performed at weekly intervals from Week 2 (Day +14 ± 2 Days) through Week 4 (Day +28 ± 
2 Days) or until the date of engraftment, whichever occurs first: 
• Physical examination. 
• ECOG performance status.  
• Vital signs (systolic and diastolic blood pressures, heart rate, respiration rate and body 
temperature) and body weight. 
• Full serum chemistry panel (sodium, potassium, chloride, magnesium, bicarbonate, glucose, 
total protein, albumin, calcium, phosphate, uric acid, BUN, creatinine, total bilirubin, 
alkaline phosphatase, LDH, SGOT, SGPT, and creatinine clearance).  
• Toxicity grading and evaluation for AEs/SAEs according to NCI-CTC AE Version 4.0. 
• Record concomitant medications. 
8.2.3.3 
End of Study Evaluation (Day 100) or Study Discontinuation/Early Termination 
The end-of-study Evaluations are to be performed between days 90 to 100.  The end-of-study 
evaluation may be performed up to seven days after study discontinuation/early termination.  The 
following evaluations will be performed at the end-of-study evaluation: 
• Physical examination. 
• ECOG performance status.  
• Vital signs (systolic and diastolic blood pressures, heart rate, respiration rate, and body 
temperature) and body weight. 
• Hematology (RBC, hemoglobin, hematocrit, platelet count, WBC with manual differential, 
and reticulocyte count). 


CONFIDENTIAL 
 
Cydex Pharmaceuticals, Inc.  
CDX-353-001 
 
Melphalan HCl for Injection (Propylene Glycol-Free) 
 
 
43 
 
• Full serum chemistry panel (sodium, potassium, chloride, magnesium, bicarbonate, glucose, 
total protein, albumin, calcium, phosphate, uric acid, BUN, creatinine, total bilirubin, 
alkaline phosphatase, LDH, SGOT, SGPT, and creatinine clearance).  
• Multiple myeloma panel 
• Bone marrow biopsy 
• Toxicity grading and evaluation for AEs/SAEs according to NCI-CTC AE Version 4.0. 
• Concomitant medications.  
8.3 Methods of Data Collection 
8.3.1 
Pharmacokinetic Evaluations 
Blood samples will be collected at the time points indicated in Table 2 (within ±5 min).  The 
concentration of “total” melphalan in these samples will be analyzed by a bioanalytical 
laboratory, using a validated LC/MS/MS method (Davies 2000). Full details of the methodology 
will be presented in the bioanalytical report, which will be appended to the clinical study report.  
PK evaluation will be based on the determination of the following parameters, including (but not 
limited to):  AUC0–t, AUCt-inf, Cmax, Tmax, t1/2, and kel. 
8.3.1.1. 
Pharmacokinetic Blood Sampling 
Serial blood samples for the PK of Melphalan HCl for Injection (Propylene Glycol-Free) will be 
collected on Day -2.  Pharmacokinetic samples will not be collected on subsequent patient visits.  
Sampling will require a peripheral intravenous catheter separate from the infusion site. 
Seven-milliliter venous blood samples for PK analysis of Melphalan HCl for injection 
(propylene glycol free) will be withdrawn through an indwelling peripheral intravenous cannula 
separate from the infusion site at 0 (pre-dose), 10, 20, 30, 60, 90, 120, 180,240 and 360 minutes 
within after the completion of Melphalan infusion.  The predose blood sample will be collected 
within 60 minutes prior to dose of Melphalan HCl for injection (propylene glycol free).  The 
actual blood sample collection times will be recorded.  Blood collection times for 10 minutes 
through 60 minutes must be obtained within ± 5 minutes.  Blood samples will be collected in 
blood collection tubes containing K2 EDTA as an anticoagulant.  Immediately following 
collection, the blood specimen should be put on ice and centrifuged within 20 minutes of the 
collection time.  The blood specimen must be centrifuged at 4 °C at 3000 × g for 10 minutes to 
obtain the plasma supernatant.  Two equal aliquots of plasma will be transferred to 
polypropylene tubes and immediately frozen in a -20 °C freezer.   
All plasma samples will be stored frozen (less than approximately -20 oC), until they are shipped 
to the analytical facility.  Prior to shipping, the samples will be packed into thermal insulated 
containers and packed in sufficient dry ice to assure they remain frozen for a minimum of 
72 hours and protected from breakage during shipment.  Samples will be shipped by overnight 
priority courier.  The samples will be divided into two shipments, each containing one aliquot of 
plasma for each time point.  After receipt of verification that the first shipment was received by 
the analytical facility, the second shipment will be sent. 


CONFIDENTIAL 
 
Cydex Pharmaceuticals, Inc.  
CDX-353-001 
 
Melphalan HCl for Injection (Propylene Glycol-Free) 
 
 
44 
 
All samples will be shipped to: 
KCAS Bioanalytical Services  
12400 Shawnee Mission Parkway 
Shawnee, KS  66216 USA  
Phone: (913) 248-3000 
8.3.2 
Efficacy Evaluations 
8.3.2.1 
Hematology Parameters for Myeloablation and Engraftment  
Efficacy evaluations (myeloablation and engraftment) will be measured through the collection of 
hematology parameters (RBC, hemoglobin, hematocrit, platelet count, WBC with manual 
differential, and reticulocyte count) daily until engraftment.  
Engraftment: ANC recovery is defined as an absolute neutrophil count (ANC) of ≥ 0.5 x 10^9 /L 
(500/mm3 ) for three consecutive laboratory values obtained on different days. Date of ANC 
recovery is the date of the first of three consecutive laboratory values where the ANC is ≥ 0.5 x 
10^9 /L. Platelet recovery is reported when the recipient’s platelet count is ≥ 20 x 10^9 /L seven 
days after platelet transfusion and is maintained for three consecutive lab values obtained on 
different days. 
 
8.3.2.2    Day 100 Myeloma Response 
Myeloma-specific response evaluation will be performed between days 90 to 100 through the 
collection of bone marrow, hematology and urine parameters (protein electrophoresis, 
immunofixation, free light chain, marrow aspirate cytology, flow cytometry and 
immunohistochemistry). Responses will be assigned based on IMWG Uniform Response criteria 
(Appendix I; Kyle RA, Rajkumar SV et al. Criteria for diagnosis, staging, risk stratification and 
response assessment of multiple myeloma. Leukemia 2009; 23:3).   
8.3.3 
Safety Evaluations 
8.3.3.1 
Adverse Event Assessment 
The investigator has the responsibility for assessing the safety of the subjects and study integrity.  
Subjects will be monitored for AEs during study participation (beginning at the time informed 
consent is obtained) and until Day 100.  Any abnormal laboratory test result that on confirmation 
the investigator considers clinically significant should be recorded as an AE, even if the subject 
reports no symptoms compatible with such laboratory findings.  AEs will be classified according 
to the Medical Directory for Regulatory Activities (MedDRA) and AEs and laboratory 
abnormalities will be graded according to the NCI CTCAE grading system and recorded on 
CRFs. (See http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-
14_QuickReference_5x7.pdf for a complete description of NCI CTCAE Grading). 
Complete details of reporting adverse events, including the definition of drug-related AEs, are 
provided in Section 9. 


CONFIDENTIAL 
 
Cydex Pharmaceuticals, Inc.  
CDX-353-001 
 
Melphalan HCl for Injection (Propylene Glycol-Free) 
 
 
45 
 
8.3.3.2 
Clinical Laboratory Investigations 
Institutional CLIA-certified laboratories will perform all study-related clinical laboratory tests.  
Blood samples for hematology analytes, clinical chemistry analytes, serum pregnancy tests and 
urine samples for urinalysis will be prepared using standard procedures.  The panels of 
laboratory tests to be performed at the visits indicated in Table 2 are shown below: 
Hematology:  
RBC, hemoglobin, hematocrit, platelet count, WBC with manual 
differential and reticulocyte count 
Full Serum 
Chemistry: 
Sodium, potassium, chloride, magnesium, glucose, bicarbonate, 
total protein, albumin, calcium, phosphate, uric acid, BUN, 
creatinine, total bilirubin, alkaline phosphatase, LDH, SGOT, 
SGPT, creatinine clearance (measured or calculated). 
Basic Serum 
Chemistry: 
Sodium, potassium, chloride, glucose, creatinine, bicarbonate, and 
BUN. 
Electrolyte 
Panel: 
Sodium, potassium, chloride, bicarbonate. 
Liver Function 
Panel: 
SGOT, SGPT, alkaline phosphatase and total bilirubin. 
Urinalysis: 
Specific gravity, pH, protein, glucose, ketones, nitrite, RBCs and 
WBCs. 
Serology: 
Serum titers for CMV, HSV, EBV, hepatitis panel, WNV, RPR for 
syphilis HIV antibodies. 
For females, a serum pregnancy test will be performed during the pretreatment period. 
Creatinine clearance may be calculated, using the Cockgraft-Gault equation:   
Males:  (140 - age) (lean body weight in kg)
serum creatinine × 72
  
Females:  (140 - age) (lean body weight in kg) (0.85)
serum creatinine × 72
   
Laboratory reports should be reviewed by the investigator or delegated physician.  The 
investigator will assess clinical significance for out-of-range parameters.   


CONFIDENTIAL 
 
Cydex Pharmaceuticals, Inc.  
CDX-353-001 
 
Melphalan HCl for Injection (Propylene Glycol-Free) 
 
 
46 
 
8.3.3.3 
ECOG Performance Status 
ECOG performance status will be assessed at pretreatment, prior to administration of Melphalan 
HCl for injection (propylene glycol free) day -2, weekly during the follow-up period (as per 
Section 8.2.3.2) and at the end-of-study evaluation as follows: 
Grade 
ECOG Performance Status 
0 
Fully active, able to carry on all predisease performance without restriction. 
1 
Restricted in physically strenuous activity but ambulatory and able to carry out work of a 
light or sedentary nature (e.g., light house-work, office work). 
2 
Ambulatory and capable of all self-care but unable to carry out any work activities.  Up 
and about more than 50% of waking hours. 
3 
Capable of only limited self-care, confined to bed or chair more than 50% of waking 
hours. 
4 
Completely disabled.  Cannot carry out any self-care.  Totally confined to bed or chair. 
 
 
8.3.3.4 
Body Weight, Height, and Body Surface Area 
Height without shoes in inches and body weight in kg will be recorded during the pretreatment 
period.  BSA will be calculated immediately prior to dosing.  Body weight will be measured 
during the pretreatment period, prior to administration of Melphalan HCl for injection (propylene 
glycol free), weekly during the follow-up period (as per Section 8.2.3.1), and at the end-of-study 
evaluation.   
8.3.3.5 
Physical Examinations 
Physical examinations will include examination of general appearance, skin, neck (including 
thyroid), eyes, ears, nose, throat, heart, lungs, abdomen, lymph nodes, extremities and nervous 
system.  Physical examinations will be performed during the pretreatment period, prior to 
administration of Melphalan HCl for injection (propylene glycol free) on day -2, weekly during 
the follow-up period (as per Section 8.2.3.1), and at the end-of-study evaluation. 
8.3.3.6 
Vital Signs 
Vital signs will include systolic and diastolic blood pressures, radial pulse rates and respiratory 
rates.  All vital signs will be obtained after the patient has been in the supine position for at least 
five minutes.  Vital signs will be taken prior to administration of Melphalan HCl for injection 
(propylene glycol free) and every hour after infusion for the first 4 hours.  Vital signs, including 
body temperature, will be taken during the pretreatment period, weekly during the follow-up 
period (as per Section 8.2.3.1), and at the end-of-study evaluation.   


CONFIDENTIAL 
 
Cydex Pharmaceuticals, Inc.  
CDX-353-001 
 
Melphalan HCl for Injection (Propylene Glycol-Free) 
 
 
47 
 
9 ADVERSE EVENT MANAGEMENT 
9.1 Definition of an Adverse Event 
An AE is defined as any untoward medical occurrence in a subject administered a medicinal 
product, which does not necessarily have a causal relationship with this treatment.  An AE can 
therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of a medicinal (investigational) product, 
whether or not related to the medicinal (investigational) product.  This includes an exacerbation 
of pre-existing conditions or events, intercurrent illnesses, drug interaction or the significant 
worsening of the indication under investigation that is not recorded elsewhere in the CRF under 
specific efficacy assessments.  Anticipated fluctuations of pre-existing conditions, including the 
disease under study that does not represent a clinically significant exacerbation or worsening 
need not be considered AEs. 
It is the investigator’s responsibility to document all AEs that occur during the study.  AEs will 
be elicited by asking the subject a nonleading question, for example, “Have you experienced any 
new or changed symptoms since we last asked/since your last visit?”  AEs should be reported on 
the appropriate page of the CRF. 
9.2 Definition of a Serious Adverse Event 
An SAE is any untoward medical occurrence that occurs at any dose (including after informed 
consent is given and prior to dosing) which either: 
1. Results in death. 
2. Is life threatening (subject is at immediate risk of death from the event as it occurred). 
3. Requires in-subject hospitalization (formal admission to a hospital for medical reasons) 
or prolongation of existing hospitalization. 
4. Results in persistent or significant disability/incapacity. 
5. Results in a congenital anomaly/birth defect. 
Important medical events that may not result in death, are not life threatening, or do not require 
hospitalization may be considered SAEs when, based upon appropriate medical judgment, they 
may jeopardize the subject and may require medical or surgical intervention to prevent one of the 
outcomes listed in this definition.  Examples of such events include allergic bronchospasm 
requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions 
that do not result in in-subject hospitalization, or the development of drug dependency or drug 
abuse. 
Hospitalizations for elective surgery or other medical procedures that are not related to a 
treatment-emergent AE are not considered SAEs. 


CONFIDENTIAL 
 
Cydex Pharmaceuticals, Inc.  
CDX-353-001 
 
Melphalan HCl for Injection (Propylene Glycol-Free) 
 
 
48 
 
9.3 Recording of Adverse Events and Serious Adverse Events 
Any AE is to be recorded in the CRF.  In order to avoid vague, ambiguous or colloquial 
expressions, the AE should be recorded in standard medical terminology rather than the subject’s 
own words.  Whenever possible, the investigator should combine signs and symptoms that 
constitute a single diagnosis. 
The existence of an AE may be concluded from a spontaneous report of the subject; from the 
physical examination; or from special tests like ECG, laboratory assessments, or other study-
specified tests (source of AE). 
AEs may occur in the specified follow-up period.  All AEs, whether drug-related or not, 
regardless of the interval since the last administration of the study medication, should be treated 
as any other AE occurring during the treatment with study medication. 
Each AE is to be evaluated for duration, severity, seriousness and causal relationship to the 
investigational drug.  The action taken and the outcome must also be recorded. 
9.4 Intensity of Adverse Events 
The severity of the AE will be graded according to the NCI CTCAE Grading Scale (See the NCI 
CTCAE web page at http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-
14_QuickReference_5x7.pdf for details).  For AEs not covered by NCI CTCAE, the severity will 
be characterized as “mild, moderate or severe” according to the following definitions: 
1. Mild events are usually transient and do not interfere with the subject’s daily activities. 
2. Moderate events introduce a low level of inconvenience or concern to the subject and 
may interfere with daily activities. 
3. Severe events interrupt the subject’s usual daily activities. 
9.5 Relationship of Adverse Events to Study Drug 
The investigator will make a judgment regarding whether or not the AE was related to study 
drug, as outlined in the following table: 
None: 
The AE must definitely be caused by the subject’s clinical state, or the study 
procedure/conditions (i.e., it has no association with the study drug). 
Improbable: 
The temporal association between the AE and the study drug is such that the 
study drug is not likely to have any reasonable association with the AE. 
Possible: 
The AE follows a reasonable temporal sequence from the time of drug 
administration, but could have been produced by the subject’s clinical state or 
the study procedures/conditions. 


CONFIDENTIAL 
 
Cydex Pharmaceuticals, Inc.  
CDX-353-001 
 
Melphalan HCl for Injection (Propylene Glycol-Free) 
 
 
49 
 
Probable: 
The AE follows a reasonable temporal sequence from the time of study drug 
administration, abates upon discontinuation of the study drug and cannot be 
reasonably explained by the known characteristics of the subject’s clinical 
state. 
Definite: 
The AE follows a reasonable temporal sequence from the time of study drug 
administration, abates upon discontinuation of the study drug and reappears 
when the study drug is introduced. 
 
 
9.6 Follow-Up of Adverse Events and Serious Adverse Events 
 All Adverse events will be followed for seven days after the date of engraftment or until any 
treatment-emergent adverse event or laboratory abnormality has resolved or is otherwise 
explained.  
9.7 Post-study Adverse Events and Serious Adverse Events 
All unresolved AEs should be followed by the investigator until the events are resolved, the 
subject is lost to follow-up, or the AE is otherwise explained.  At the last scheduled visit, the 
investigator should instruct each subject to report any subsequent event(s) that the subject, or the 
subject’s personal physician, believes might reasonably be related to participation in this study.  
The investigator should notify Spectrum of any death or AE occurring at any time after a subject 
has discontinued or terminated study participation that may reasonably be related to this study.  
Spectrum should also be notified if the investigator should become aware of the development of 
cancer or of a congenital anomaly in a subsequently conceived offspring of a subject that has 
participated in this study. 
9.8  Regulatory Aspects of Adverse Event Reporting 
SAEs must be reported to the IRB and FDA within 24 hours of first knowledge of the event by 
study personnel, followed by a fax of the SAE Form (which can be found in the Regulatory 
Office documents file).  It is important that the investigator provide his/her assessment of 
relationship to study drug at the time of the initial report. 
The investigator is responsible for submitting reports of AEs associated with the use of the drug 
that are both serious and unexpected to the FDA according to 21 CFR 312.32.  All investigators 
participating in ongoing clinical studies with the study medication will receive copies of these 
reports for prompt submission to their Institutional Review Board (IRB). 
10 STATISTICAL METHODS 
Descriptive statistical methods will be used to summarize the data from this study.  Unless stated 
otherwise, the term “descriptive statistics” refers to number of subjects (n), mean, median, 
standard deviation, minimum and maximum for continuous data, and frequencies and 
percentages for categorical data.   
All statistical analyses will be conducted with the SAS® System, Version 9.1.3 or higher. 


CONFIDENTIAL 
 
Cydex Pharmaceuticals, Inc.  
CDX-353-001 
 
Melphalan HCl for Injection (Propylene Glycol-Free) 
 
 
50 
 
10.1 Data Collection Methods 
The data will be recorded on the Oncore-CRF.  The Investigator must submit a completed CRF 
for each subject who signs an informed consent form (ICF), regardless of duration.  All 
documentation supporting the CRF data, such as laboratory or hospital records, must be readily 
available to verify entries in the CRF. 
Documents (including laboratory reports, hospital records subsequent to SAEs, CT scan results, 
etc.) should not carry the subject’s name.  This will help to ensure subject confidentiality. 
10.2 Statistical Analysis Plan 
A statistical analysis plan (SAP) will be created prior to the review of any data.  This document 
will provide a more technical and detailed description of the proposed data analysis methods and 
procedures. 
10.3 Sample Size Estimates 
A sample size of 24 patients is planned for this study.  The mean±SD results of AUC0-t and Cmax 
of 100 mg/m2 melphalan dose from a previously conducted study were 376,577±93,401 
min·ng/mL and 4374 ± 1050 ng/mL respectively. Twenty-four patients will provide ±10% width 
for the 90% CI around the point estimates of AUC0-t and Cmax in this study. A study size of 24 
patients would also provide for a 95% confidence interval having a width of ±20% to estimate an 
AE incidence rate for common AEs occurring at a frequency of 25 -30%. 
10.4 Analysis Populations 
The PK evaluable population is defined as all patients, who completed dosing and adequate 
subsequent PK blood draws for the calculation of AUC and Cmax for Melphalan HCl for injection 
(propylene glycol free).  PK analyses will be performed on the evaluable population. 
AllA enrolled patients receivingingMelphalan HCl for injection (propylene glycol free) will be 
defined as the population for analyses.  All safety and efficacy analyses will be performed on all 
patients who received study medication. 
10.5 Interim and End-of-Study Analyses 
Interim Analysis 
An independent DSMB at the Medical College of Wisconsin will review safety data on an 
ongoing basis (see Section 11.6.1).  Safety analyses will be presented in a manner consistent with 
the presentations intended for the final analysis according to CTCAE v 4.0 criteria 
End-of-Study Analysis 
A final analysis is planned after the last subject completes or discontinues the study and the 
resulting clinical database has been cleaned, quality checked, and locked. 


CONFIDENTIAL 
 
Cydex Pharmaceuticals, Inc.  
CDX-353-001 
 
Melphalan HCl for Injection (Propylene Glycol-Free) 
 
 
51 
 
10.6 Pharmacokinetic Analyses 
PK parameters will be determined by nonparametric PK data analysis techniques.  PK 
parameters computed from plasma drug concentration time data will include, but not necessarily 
be limited to the following parameters: 
• Cmax derived from the individual raw data. 
• Tmax derived from the individual raw data. 
• Apparent terminal first-order elimination rate constant (kel). 
• Apparent elimination t1\2. 
• Area under the plasma concentration-time curve to the last measurable time point (AUC0–t) 
calculated by the trapezoidal rule. 
• Area under the plasma concentration-time curve to infinity (AUC0-∞): AUC0–t + area under 
the plasma concentration-time curve from the last measurable time point extrapolated to 
infinity determined from the concentration at the last measurable time point divided by the 
kel. 
The plasma concentrations and pharmacokinetic parameters for Melphalan HCl for injection 
(propylene glycol free) will be summarized in the following manner: 
Descriptive Statistics 
Arithmetic means, standard deviations and coefficients of variation will be calculated for the 
parameters listed above.  Additionally, geometric means will be calculated for AUC0-t, AUC0-∞, 
and Cmax. 
10.7 Efficacy Analyses 
10.7.1 Efficacy Endpoints 
The rates of myeloablation and engraftment will be determined based on the following 
definitions: 
Myeloablation is defined as any one of the following: 
• ANC <0.5 × 109/L. 
• Platelet count <20,000/mm3 or bleeding requiring transfusion. 
The first of two consecutive days for which cell counts drop below these cut-off levels will be 
recorded as the date of myeloablation. 
Engraftment is defined as per Section 8.3.2.1 as: 
ANC recovery is defined as an absolute neutrophil count (ANC) of ≥ 0.5 x 10^9 /L (500/mm3) 
for three consecutive laboratory values obtained on different days. Date of ANC recovery is the 
date of the first of three consecutive laboratory values where the ANC is ≥ 0.5 x 10^9 /L. Platelet 


CONFIDENTIAL 
 
Cydex Pharmaceuticals, Inc.  
CDX-353-001 
 
Melphalan HCl for Injection (Propylene Glycol-Free) 
 
 
52 
 
recovery is reported when the recipient’s platelet count is ≥ 20 x 10^9 /L seven days after platelet 
transfusion and is maintained for three consecutive lab values obtained on different days. Time 
to myeloablation will be calculated as the time from receiving Melphalan for injection 
(propylene glycol free) to the date of myeloablation. 
Time to engraftment will be calculated as the time from transplant to the date of engraftment.  
10.7.2 Analysis of Efficacy Endpoints 
Efficacy analyses will be performed on allall patients who received study medication. 
The rates of myeloablation and engraftment during the study will be calculated and will be 
summarized descriptively.   
Time to myeloablation and time to engraftment will be calculated for each patient and 
summarized, using Kaplan-Meier / cumulative incidence. 
Myeloma responses will be calculated for each patient and summarized. 
10.8 Safety Analyses 
Safety analyses will be performed all patientsalls who received study medication.  The following 
safety analyses will be performed for this study and will include all collected data through the 
final study visit: 
• Incidence of all treatment-emergent AEs and drug-related treatment-emergent AEs by system 
organ class and preferred term. 
• Incidence of all treatment-emergent AEs by system organ class, preferred term, and severity. 
• Incidence of all treatment-emergent AEs and treatment-emergent drug-related AEs by 
CTCAE v4.0 grade. 
• Incidence of treatment-emergent AEs, treatment-emergent drug-related AEs, and 
treatment-emergent CTCAE v4.0 Grade 3 or 4 AEs by preferred term in descending 
frequency. 
• Incidence of all AEs that led to discontinuation of study medication. 
• Incidence of all SAEs and drug-related SAEs, including deaths. 
• Summary of changes in laboratory parameters from baseline to postdose time points. 
• Laboratory parameters summarized by CTCAE v4.0 Grade (frequency and shifts). 
• Summary of changes in vital signs from baseline to postdose time points. 
10.9 General Issues for Statistical Analysis 
10.9.1 Multiple Comparisons and Multiplicity 
There are no planned adjustments for multiplicity. 


CONFIDENTIAL 
 
Cydex Pharmaceuticals, Inc.  
CDX-353-001 
 
Melphalan HCl for Injection (Propylene Glycol-Free) 
 
 
53 
 
10.9.2 Subgroups 
There are no planned subgroup analyses. 
10.9.3 Missing Data 
Every effort will be made to obtain required data at each scheduled evaluation from all subjects 
who have been enrolled.  There will be no imputation for missing data. 
11 STUDY ADMINISTRATION 
11.1 Regulatory and Ethical Considerations 
11.1.1 Regulatory Authority Approvals 
This study will be conducted in compliance with the protocol, GCPs including ICH of Technical 
Requirements for Registration of Pharmaceuticals for Human Use Guidelines, FDA regulatory 
requirements, and in accordance with the ethical principles of the Declaration of Helsinki.   
The investigator should submit written reports of clinical study status to the IRB annually or 
more frequently, if requested by the IRB.  A final study notification should also be forwarded to 
the IRB within 15 days after the study is completed or in the event of premature termination of 
the study.  Copies of all contact with the IRB should be maintained in the study documents file.  
Copies of the clinical study status reports (including termination) should be provided to 
Spectrum. 
11.1.2 Institutional Review Board Approvals 
Before initiation of the study at each investigational site the protocol, informed consent form, 
subject information sheet, and any other relevant study documentation will be submitted to the 
appropriate IRB.  Written approval of the study must be obtained before the study center can be 
initiated or the investigational medicinal product is released to the investigator.  Any necessary 
extensions or renewals of IRB approval must be obtained, in particular, for changes to the study, 
such as modification of the protocol, informed consent form and/or written information provided 
to subjects and/or other procedures. 
The investigator will report promptly to the IRB any new information that may adversely affect 
the safety of the subjects or the conduct of the study.  On study completion, the investigator will 
provide the IRB with a study outcome report. 
11.1.3 Subject Informed Consent 
Signed informed consent must be obtained from each subject (or legally acceptable 
representative when appropriate) prior to performing any study related procedures.  Each subject 
should be given both verbal and written information describing the nature and duration of the 
clinical study.  The informed consent process should take place under conditions where the 
subject has adequate time to consider the risks and benefits associated with his/her participation 


CONFIDENTIAL 
 
Cydex Pharmaceuticals, Inc.  
CDX-353-001 
 
Melphalan HCl for Injection (Propylene Glycol-Free) 
 
 
54 
 
in the study.  Subjects will not be screened or treated until the subject has signed an approved 
ICF written in a language in which the subject is fluent. 
The ICF used must be approved both by Spectrum and by the reviewing IRB.  The informed 
consent should be in accordance with the current revision of the Declaration of Helsinki, current 
ICH and GCP guidelines, and Spectrum policy. 
The investigator must explain to potential subjects or their legal representatives the aims, 
methods, reasonably anticipated benefits, and potential hazards of the trial and any discomfort it 
may entail.  Subjects will be informed that they are free not to participate in the trial and that 
they may withdraw consent to participate at any time.  They will be told that refusal to 
participate in the study will not prejudice future treatment.  They will also be told that their 
records may be examined by regulatory authorities and authorized persons but that personal 
information will be treated as strictly confidential and will not be publicly available.  Subjects 
must be given the opportunity to ask questions.  After this explanation and before entry into the 
trial, consent should be appropriately recorded by means of the subject’s or his/her legal 
representative’s dated signature.  If a subject and his/her legal representative are unable to read, 
an impartial witness must be present during the entire informed consent discussion.  The 
signature of the impartial witness will certify the subject’s consent.  The subject should receive a 
signed and dated copy of the ICF.  The original signed informed consent should be retained in 
the study files.  The investigator shall maintain a log of all subjects, who sign the ICF, and 
indicate if the subject was enrolled into the study or reason for failure. 
11.2 Study Monitoring 
During trial conduct, the investigator will ensure that the protocol and GCPs are being followed.  
The investigator is responsible to confirm that the data recorded on CRFs are accurate.  The 
investigator and institution will allow Spectrum monitors or its designees and appropriate 
regulatory authorities direct access to source documents to perform this verification. 
11.3 Quality Assurance 
The trial site may be subject to review by the IRB, and/or to quality assurance audits performed 
by Spectrum or its designee, and/or to inspection by appropriate regulatory authorities. 
11.4 Study Termination and Site Closure 
Spectrum reserves the right to discontinue the trial prior to inclusion of the intended number of 
subjects but intends only to exercise this right for valid scientific or administrative reasons.  
After such a decision, the investigator must contact all participating subjects immediately after 
notification.  All study materials must be collected and all CRFs completed to the greatest extent 
possible. 
11.5 Records Retention 
To enable evaluations and/or audits from regulatory authorities, the investigator agrees to keep 
records, including the identity of all participating subjects (sufficient information to link records, 


CONFIDENTIAL 
 
Cydex Pharmaceuticals, Inc.  
CDX-353-001 
 
Melphalan HCl for Injection (Propylene Glycol-Free) 
 
 
55 
 
case report forms and hospital records), all original signed informed consent forms, copies of all 
case report forms and detailed records of treatment disposition.  The records should be retained 
by the investigator according to local regulations or as specified in the Clinical Trial Agreement, 
whichever is longer. 
If the investigator relocates, retires or for any reason withdraws from the study, the study records 
may be transferred to an acceptable designee, such as another investigator, another institution.  
The investigator must obtain Spectrum’s written permission before disposing of any records. 
11.6 Study Organization 
11.6.1 Data and Safety Monitoring Board 
This study will be reviewed by the Medical College of Wisconsin Cancer Center Data and Safety 
Monitoring Committee (MCWCC DSMC). A summary of the MCWCC DSMC activities are as 
follows:  
• Review the clinical trial for data integrity and safety  
• Review all unexpected grade 3, and all grade 4, and 5 adverse events, as well as any 
others requiring expedited reporting as defined in this protocol. Grade 4 & 5 events must 
be reported to the DSMC within 5 calendar days of study staff’s knowledge. 
• Review all DSM reports  
• Submit a summary of any recommendations related to study conduct  
• Terminate the study if deemed unsafe for patients  
The DSMC will review safety data at a minimum of every month (based on the accrual rate). (If 
there are fewer than one patient enrolled/accrued, there is no basis for review.)  
A copy of the MCWCC Data and Safety Monitoring Plan and membership roster will be 
maintained in the study research file and updated as membership changes. The committee will 
review reports from the study PI twice annually (or more frequently if needed) and provide 
recommendations on trial continuation, suspension or termination as necessary.  
Any available DSMC letters will be submitted to the IRB of record as required. 
11.7 Confidentiality of Information 
Spectrum affirms the subject’s right to protection against invasion of privacy.  Only a subject 
identification number and/or initials will identify subject data retrieved by Spectrum.  However, 
in compliance with federal regulations, Spectrum requires the investigator to permit Spectrum’s 
representatives and, when necessary, representatives of the FDA or other regulatory authorities 
to review and/or copy any medical records relevant to the study. 


CONFIDENTIAL 
 
Cydex Pharmaceuticals, Inc.  
CDX-353-001 
 
Melphalan HCl for Injection (Propylene Glycol-Free) 
 
 
56 
 
Spectrum will ensure that the use and disclosure of protected health information obtained during 
a research study comply with the Health Insurance Portability and Accountability Act (HIPAA) 
Privacy Rule.  The rule provides federal protection for the privacy of protected health 
information by implementing standards to protect and guard against the misuse of individually 
identifiable health information of subjects participating in sponsored Clinical Trials. 
"Authorization" is required from each research subject, i.e., specified permission granted by an 
individual to a covered entity for the use or disclosure of an individual's protected health 
information.  A valid authorization must meet the implementation specifications under the 
HIPAA Privacy Rule.  Authorization may be combined in the informed consent document 
(approved by the IRB) or it may be a separate document, (approved by the IRB/IEC) or provided 
by the investigator or sponsor (without IRB approval).  It is the responsibility of the investigator 
and institution to obtain such waiver/authorization in writing from the appropriate individual.   
11.8 Study Publication 
All data generated from this study are the property of Spectrum and shall be held in strict 
confidence along with all information furnished by Spectrum.  Independent analysis and 
publication of these data by the investigator or any member of his/her staff are not permitted 
without prior written consent of Spectrum.  Written permission to the investigator will be 
contingent on the review by Spectrum of the statistical analysis and manuscript and will provide 
for nondisclosure of Spectrum confidential or proprietary information.  In all cases, the parties 
agree to submit all manuscripts or abstracts to all other parties 30 days prior to submission.  This 
will enable all parties to protect proprietary information and to provide comments, based on 
information that may not yet be available to other parties. 
12 REFERENCES 
Aljitawi OS, Ganguly S, Abhyankar SH, et al. Phase IIa cross-over study of propylene glycol-
free melphalan (LGD-353) and alkeran in multiple myeloma autologous transplantation. Bone 
Marrow Transplant. 2014;49(8):1042–5. 
Alkeran (melphalan hydrochloride) for Injection prescribing information. Celgene Corporation, 
Summit, NJ; March 2008. Alkeran (melphalan) Tablets prescribing information. Celgene 
Corporation, Summit, NJ; June 2007.  American Cancer Society. Cancer Facts & Figures, 2008. 
Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG. A randomized prospective trial of 
autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med, 
1996; 335:91–97. 
Bensinger W. Stem-Cell Transplantation for multiple myeloma in the era of novel drugs. J Clin 
Oncol, 2008; 26(3):480–492. 
Davies I D, Allanson J P; Causon R C.  Rapid determination of the anti-cancer drug melphalan 
(Alkeran) in human serum and plasma by automated solid-phase extraction and liquid 
chromatography-tandem mass spectrometry. Chromatographia, 2000, 52, Suppl: S92–S97. 
 
Facon T, Darre S. Frontline treatment i multiple myeloma paients not eligible for stem-cell 
transplantation. Best Pract Res Cl Ha, 2007; 20(4):737–746. 


CONFIDENTIAL 
 
Cydex Pharmaceuticals, Inc.  
CDX-353-001 
 
Melphalan HCl for Injection (Propylene Glycol-Free) 
 
 
57 
 
Hahn T, Wingard JR, Anderson KC, Bensinger WI, Berenson JR, et al. The Role of Cytotoxic 
Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Multiple Myeloma: An 
Evidence-Based Review. Biol Blood Marrow Transplant, 2003; 9:4–37. 
Hari PN, Ajitawi O, Arce-Lara C et al. Results of a Phase II Study of Propylene Glycol (PG)-
Free, Captisol-Enabled Melphalan Conditioning for Autologous Hematopoietic Stem Cell 
Transplantation (AHCT) in Patients with Multiple Myeloma (MM). Biol Blood Marrow 
Transplant, 2015;21(2), S138. 
Hari P, Aljitawi OS, Arce-lara C, et al. A Phase iib, multicenter, open-label, safety, and efficacy 
study of high-dose, propylene glycol-free melphalan hydrochloride for injection (EVOMELA) 
for myeloablative conditioning in multiple myeloma patients undergoing autologous 
transplantation. Biol Blood Marrow Transplant. 2015;21(12):2100–5. 
Lazarus HM, Hamadani M, Hari PN. Autologous stem cell transplantation. In: DeVita VT. 
DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th ed. 
Philadelphia, PA:  Wolters Kluwer Health; 2014:  1907–1916. 
 
Kühne A, Sezer O, Heider U, Meineke I, Muhlke S, et al. Population pharmacokinetics of 
melphalan and glutathione S-transferase polymorphisms in relation to side effects. Clin 
Pharmacol Ther, 2007; 83(5):749–757. 
Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, et al. Improved survival in 
multiple myeloma and the impact of novel therapies. Blood, 2008; 111(5):2516–2520. 
Kyle RA, Rajkumar SV. Multiple myeloma. Blood, 2008; 111(6):2962–2972. 
Kyle RA, Rajkumar SV. Multiple Myeloma. N Engl J Med, 2004a; 351(18):1860–1873. 
Kyle RA, Rajkumar SV et al. Criteria for diagnosis, staging, risk stratification and response 
assessment of multiple myeloma. Leukemia 2009; 23:3  
Moreau P, Kergueris MF, Milipied N, LeTotorec S, Mahé B. A pilot study of 220 mg/m2 
melphalan followed by autologous stem cell transplantation in patients with advanced 
hematological malignancies: pharmacokinetics and toxicity. Br J Haematol, 1996; 95:527–530. 
Moreau P, Milipied N, Mahé B, Juge-Morineau N, Rapp MJ. Melphalan 220 mg/m2 followed by 
peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma. Bone 
Marrow Transplant, 1999; 23:1000–1006. 
Nath CE, Shaw PJ, Trotman J et al. Population pharmacokinetics of melphalan in patients with 
multiple myeloma undergoing high dose therapy. Br J Clin Pharmacol. 2010 May;69(5):484–97. 
National Comprehensive Cancer Network, Inc. Clinical Practice Guidelines in Oncology™. 
Multiple Myeloma, V4.2015 accessed May 1 2015 at 
http://www.nccn.org/professionals/physician_gls/PDF/myeloma.pdf. 
Niesvizky R, Jayabalan DS, Christos PJ, Furst JR, Naib T, et al. BiRD 
Biaxin[clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in 
high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. 
Blood, 2008; 111(3):1101–1109. 


CONFIDENTIAL 
 
Cydex Pharmaceuticals, Inc.  
CDX-353-001 
 
Melphalan HCl for Injection (Propylene Glycol-Free) 
 
 
58 
 
Pant S, Copelan EA. Hematopoietic stem cell transplantation in multiple myeloma. Biol Blood 
Marrow Transplant, 2007; 13:877–885. 
Sarosy G, Leyland-Jones B, Soochan P, Cheson BD. The Systemic Administration of 
Intravenous Melphalan. J Clin Oncol, 1988; 6(11):1768–1782. 
Shah N, Callander N, Ganguly S et al. Hematopoietic Stem Cell Transplantation for Multiple 
Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation. Biol 
Blood Marrow Transplant. 2015 Jul;21(7):1155–66.  
Shaw PJ, Nath CE, Lazarus HM. Not too little, not too much-just right! (Better ways to give high 
dose melphalan). Bone Marrow Transplant. 2014 Dec;49(12):1457–65.  
Wilson KC, Reardon C, Theodore AC, Farber HW. Propylene glycol toxicity: a severe iatrogenic 
illness in ICU patients receiving IV benzodiazepines: a case series and prospective, observational 
pilot study. Chest, 2005; 128:1674–1681. 
Yaucher NE, Fish JT, Smith HW, Wells JA. Propylene glycol-associated renal toxicity from 
lorazepam infusion. Pharmacotherapy, 2003; 23(9):1094–1099. 
Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol 
toxicity. Semin Dial, 2007; 20(3):217–219. 
 
 
 


CONFIDENTIAL 
 
Cydex Pharmaceuticals, Inc.  
CDX-353-001 
 
Melphalan HCl for Injection (Propylene Glycol-Free) 
 
 
59 
 
13 
APPENDIX I 
Response criteria in Multiple myeloma: 
CR : Negative immunofixation of serum and urine, disappearance of any soft tissue 
plasmacytomas, and < 5% plasma cells in bone marrow; in patients for whom only measurable 
disease is by serum FLC level, normal FLC ratio of 0.26 to 1.65 in addition to CR criteria is 
required; two consecutive assessments are needed. 
 
 
sCR: CR as defined plus normal FLC ratio and absence of clonal plasma cells by 
immunohistochemistry or two- to four-color flowcytometry; two consecutive assessments of 
laboratory parameters are needed. 
 
vGPR: Serum and urine M component detectable by immunofixation but not on electrophoresis 
or ≥ 90% reduction in serum M component plus urine M component <100 mg/24 h; in patients 
for whom only measurable disease is by serum FLC level, > 90% decrease in difference between 
involved and uninvolved FLC levels, in addition to VGPR criteria, is required; two consecutive 
assessments are needed. 
 
PR: ≥ 50% reduction of serum M protein and reduction in 24-hour urinary M protein by ≥ 90% 
or to < 200 mg/24 h. If serum and urine M protein are not measurable, ≥50% decrease in 
difference between involved and uninvolved FLC levels is required in place of M protein 
criteria. If serum and urine M protein and serum FLC assay are not measurable, ≥ 50% reduction 
in bone marrow plasma cells is required in place of M protein, provided baseline percentage was 
≥30%. In addition, if present at baseline, ≥50% reduction in size of soft tissue plasmacytomas is 
required. Two consecutive assessments are needed; no known evidence of progressive or new 
bone lesions if radiographic studies. 
 
 
SD: Not meeting criteria for CR, VGPR, PR, or PD; no known evidence of progressive or new 
bone lesions if radiographic studies were performed. 
 
PD: Increase of 25% from lowest response value in any of following: Serum M component with 
absolute increase ≥ 0.5 g/dL; serum M component increases ≥1 g/dL are sufficient to define 
relapse if starting M component is  ≥ 5 g/dL and/or; Urine M component (absolute increase must 
be ≥200 mg/24 h) and/or; Only in patients without measurable serum and urine M protein levels: 
difference between involved and uninvolved FLC levels (absolute increase must be > 10 
mg/dL);Only in patients without measurable serum and urine M protein levels and without 
measurable disease by FLC level, bone marrow plasma cell percentage (absolute percentage 
must be ≥ 10%) .Development of new or definite increase in size of existing bone lesions or soft 
tissue plasmacytomas. Development of hypercalcemia that can be attributed solely to plasma cell 
proliferative disorder. Two consecutive assessments before new therapy are needed. 
 
Source: Paulmbo et al. Journal Of Clinical Oncology 2014; 32:587-600 for International 
Myeloma Working group. 

SAP_001.pdf: 
STATISTICAL ANALYSIS PLAN 
 
A Phase II, Open-Label, Pharmacokinetic Study of Propylene Glycol-Free  
Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing 
Autologous Transplantation (IIS-MEL-MCW-001) 
 
 
 
 
 
 
February 20, 2016 
 
 
 
CT.gov account NCT02669615 
 
 
 
 
 
 
 
 
 
Investigator and Study Center: 
Parameswaran Hari, MD 
Medical College of Wisconsin  
Division of Hematology and Oncology 
9200 W. Wisconsin Ave. 
Milwaukee, WI 53226 
414.805.4600 
Email address: phari@mcw.e 


STATISTICAL ANALYSIS PLAN 
STATISTICAL METHODS 
Descriptive statistical methods will be used to summarize the data from this study. Unless stated 
otherwise, the term “descriptive statistics” refers to number of subjects (n), mean, median, 
standard deviation, minimum and maximum for continuous data, and frequencies and 
percentages for categorical data.  
All statistical analysis will be conducted with the SAS® System, Version 9.1.3 or higher. 
10.1 Data Collection Methods 
The data will be recorded on the Oncore-CRF. The Investigator must submit a completed CRF 
for each subject who signs an informed consent form (ICF), regardless of duration. All 
documentation supporting the CRF data, such as laboratory or hospital records, must be readily 
available to verify entries in the CRF. 
Documents (including laboratory reports, hospital records subsequent to SAEs, CT scan results, 
etc.) should not carry the subject’s name. This will help to ensure subject confidentiality. 
10.2 Statistical Analysis Plan 
A statistical analysis plan (SAP) will be created prior to the review of any data. This document 
will provide a more technical and detailed description of the proposed data analysis methods and 
procedures. 
10.3 Sample Size Estimates 
A sample size of 24 patients is planned for this study. The mean±SD results of AUC0-t and Cmax 
of 100 mg/m2 melphalan dose from a previously conducted study were 376,577±93,401 
min·ng/mL and 4374 ± 1050 ng/mL respectively. Twenty-four patients will provide ±10% width 
for the 90% CI around the point estimates of AUC0-t and Cmax in this study. A study size of 24 
patients would also provide for a 95% confidence interval having a width of ±20% to estimate an 
AE incidence rate for common AEs occurring at a frequency of 25 -30%. 
10.4 Analysis Populations 
The PK evaluable population is defined as all patients, who completed dosing and adequate 
subsequent PK blood draws for the calculation of AUC and Cmax for melphalan HCl for injection 
(propylene glycol free). PK analysis will be performed on the evaluable population. 
All enrolled patients receiving melphalan HCl for injection (propylene glycol free) will be 
defined as the population for analysis. All safety and efficacy analysis will be performed on all 
patients who received study medication. 


10.5 Interim and End-of-Study Analysis 
Interim Analysis 
An independent DSMB at the Medical College of Wisconsin will review safety data on an 
ongoing basis (see Section 11.6.1). Safety analysis will be presented in a manner consistent with 
the presentations intended for the final analysis according to CTCAE v 4.0 criteria 
End-of-Study Analysis 
A final analysis is planned after the last subject completes or discontinues the study and the 
resulting clinical database has been cleaned, quality checked, and locked. 
10.6 Pharmacokinetic Analysis 
PK parameters will be determined by nonparametric PK data analysis techniques. PK parameters 
computed from plasma drug concentration time data will include, but not necessarily be limited 
to the following parameters: 
 Cmax derived from the individual raw data. 
 Tmax derived from the individual raw data. 
 Apparent terminal first-order elimination rate constant (kel). 
 Apparent elimination t1\2. 
 Area under the plasma concentration-time curve to the last measurable time point (AUC0–t) 
calculated by the trapezoidal rule. 
 Area under the plasma concentration-time curve to infinity (AUC0-∞): AUC0–t + area under 
the plasma concentration-time curve from the last measurable time point extrapolated to 
infinity determined from the concentration at the last measurable time point divided by the 
kel. 
The plasma concentrations and pharmacokinetic parameters for melphalan HCl for injection 
(propylene glycol free) will be summarized in the following manner: 
Descriptive Statistics 
Arithmetic means, standard deviations and coefficients of variation will be calculated for the 
parameters listed above. Additionally, geometric means will be calculated for AUC0-t, AUC0-∞, 
and Cmax. 
10.7 Efficacy Analysis 
10.7.1 Efficacy Endpoints 
The rates of myeloablation and engraftment will be determined based on the following 
definitions: 


Myeloablation is defined as any one of the following: 
 ANC <0.5 × 109/L. 
 Platelet count <20,000/mm3 or bleeding requiring transfusion. 
The first of two consecutive days for which cell counts drop below these cut-off levels will be 
recorded as the date of myeloablation. 
Engraftment is defined as per Section 8.3.2.1 as: 
ANC recovery is defined as an absolute neutrophil count (ANC) of ≥ 0.5 x 10^9 /L (500/mm3) 
for three consecutive laboratory values obtained on different days. Date of ANC recovery is the 
date of the first of three consecutive laboratory values where the ANC is ≥ 0.5 x 10^9 /L. Platelet 
recovery is reported when the recipient’s platelet count is ≥ 20 x 10^9 /L seven days after platelet 
transfusion and is maintained for three consecutive lab values obtained on different days. Time 
to myeloablation will be calculated as the time from receiving melphalan for injection (propylene 
glycol free) to the date of myeloablation. 
Time to engraftment will be calculated as the time from transplant to the date of engraftment.  
10.7.2 Analysis of Efficacy Endpoints 
Efficacy analysis will be performed on all patients who received study medication. 
The rates of myeloablation and engraftment during the study will be calculated and will be 
summarized descriptively.  
Time to myeloablation and time to engraftment will be calculated for each patient and 
summarized, using Kaplan-Meier / cumulative incidence. 
Myeloma responses will be calculated for each patient and summarized. 
10.8 Safety Analysis 
Safety analysis will be performed on all patients who received study medication. The following 
safety analysis will be performed for this study and will include all collected data through the 
final study visit: 
 Incidence of all treatment-emergent AEs and drug-related treatment-emergent AEs by system 
organ class and preferred term. 
 Incidence of all treatment-emergent AEs by system organ class, preferred term, and severity. 
 Incidence of all treatment-emergent AEs and treatment-emergent drug-related AEs by 
CTCAE v4.0 grade. 
 Incidence of treatment-emergent AEs, treatment-emergent drug-related AEs, and 
treatment-emergent CTCAE v4.0 Grade 3 or 4 AEs by preferred term in descending 
frequency. 


 Incidence of all AEs that led to discontinuation of study medication. 
 Incidence of all SAEs and drug-related SAEs, including deaths. 
 Summary of changes in laboratory parameters from baseline to post-dose time points. 
 Laboratory parameters summarized by CTCAE v4.0 Grade (frequency and shifts). 
 Summary of changes in vital signs from baseline to post-dose time points.